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Currently, chronic diseases are well recognized as major contributors to global 
mortality (1) and, by 2030, it is expected that these diseases will account for more 
than three-quarters of deaths worldwide. Within chronic diseases, cardiovascular 
disease (CVD) emerged as the leading cause of global mortality (2). In two decades, 
the total number of cardiovascular (CV) deaths raised from 14.4 million to 17.5 million 
and achieved nearly 20 million in 2015, accounting for 31% of all deaths worldwide 
(2). CVD is thought to be a problem of wealthy nations, whereas infectious diseases 
are considered the main cause of mortality in developing countries. However, a large 
body of epidemiological evidence showed that in low and middle income nations, CVD 
is responsible for more deaths than infectious diseases, poor maternal/perinatal 
conditions and nutritional disorders combined (3). Thus, CVD can be considered as the 
largest simple contributor to global mortality and, according to the World Health 
Organization (WHO), CVD will continue to dominate mortality trends in the close 
future (4). The worsening of CV health around the world reflects significant global 
changes in behavior and lifestyle. The “westernization” of dietary habits and 
decreased physical activity are now practices that also threaten developing countries. 
In addition, the decline in infectious diseases and improved childhood nutrition have 
contributed to the aging of populations resulting in an increasing number of 
individuals who survive to the age at which risk factors they accrued throughout 
childhood and early adulthood, manifest as overt disease. This has resulted in an 
epidemic of CVD in the developing countries comparable to the one that took place in 
the developed world in previous decades: CVD has global dimensions. 
Over the past years, a considerable amount has been learned about the determinants 
of CVD and a series of both modifiable and non-modifiable risk factors have been 
identified. Several risk factors [i.e. age, male gender, high levels of low density 
lipoprotein (LDL) cholesterol, smoking, diabetes, hypertension and family history of 
CVD] emerged from the Framingham Study (5) and are now well-recognized risk 




individuals at risk for CV events pointing at new factors contributing to CVD 
development (6). Insulin resistance, inflammation and oxidative stress are emerging 
risk factors of paramount importance in CV risk, heavily affecting CV morbidity and 
mortality (7, 8, 9). They are closely related to pathophysiological processes, each of 
them being cause and consequence of the others in a self-perpetuating vicious cycle. 
The strict interconnection among them makes difficult to disentangle the effect of the 
single risk factor on CV system components. As experimental and epidemiologic 
research indicates, a close association between reactive oxygen species (ROS) and 
chronic inflammation exists (9). ROS can trigger the production of pro-inflammatory 
cytokines (TNFα, IL-1, IL-6), chemokines (IL-8) and pro-inflammatory transcription 
factors (NF-κB) (10) but, on the other hand, inflammation promotes oxidative stress 
(11). Oxidative stress can also lead to insulin resistance (12, 13, 14) but, at the same 
time, metabolic derangements induce oxidative stress and compromise inflammatory 
response (15) that, in turn, can causes alterations in insulin signaling pathway (13, 16). 
Insulin resistance, inflammation and oxidative stress are alterations that characterize 
a variety of chronic diseases. Impaired insulin sensitivity and subclinical low-grade 
inflammation are pervasive conditions in obesity (17, 18) and chronic kidney disease 
(19, 20) while oxidative stress is the main responsible for aging (21). 
 
OUTLINE OF THE THESIS 
The aim of this thesis is to investigate whether insulin resistance, inflammation and 
oxidative stress increase CV risk and affect survival in high-risk populations. To address 
this question, epidemiologic and genetic studies were carried out in obese individuals, 
elderly and patients with chronic kidney disease of various severity, who represent 
three populations with high CV risk. 
Schematically, the thesis is divided in two parts: Part I, which reports results from two 
cross-sectional studies, and Part II, which shows results from four prospective studies. 
Coming up, the findings are placed into perspective in the general discussion where 
General introduction and outline of the thesis 
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suggestions for future research are also addressed and, finally, a summary gives an 
overview of the thesis. 
In short: 
In Chapter 2, the expression profiles of pro-inflammatory and anti-inflammatory 
genes in abdominal subcutaneous and visceral adipose tissue in severely obese 
individuals are investigated to assess the specific contribution to inflammation of the 
two fat depots. It is recognized that important differences exist in the gene expression 
profile of subcutaneous and visceral adipose tissue but, with respect to inflammatory 
genes, results are controversial. In this respect, the basic hypothesis is that 
topography of adipose tissue accumulation is relevant for the risk of developing 
inflammation and, in turn, of enhancing the risk of CV complications. 
In Chapter 3, the hypothesis that genetic markers of insulin resistance modify the link 
between a pro-fibrotic cytokine at myocardial level, i.e. TIMP-1, and left ventricular 
(LV) mass and function in a group of dialysis patients is investigated. The background 
is based on two observations: 1) insulin resistance promotes myocardial fibrosis; 2) 
the genetic markers considered in this study were previously associated with LV 
hypertrophy in the same population of patients. 
In Chapter 4, the nature (causal vs non-causal) of the association between IL-6 and 
fatal and non-fatal CV event in a population of patients with CKD of various severity is 
determined by using the approach of Mendelian randomization to infer causality in an 
observational setting. 
Chapter 5 shows the results of a genetic association study testing whether the 
variability of the FTO gene contributes to explain mortality in 3 cohorts of patients 
with CKD of various severity. The issue is of relevance because diabetes and 
hypertension, two risk factors which have been associated to the FTO gene, rank as 
major risk factors for CKD and survival in this population. Results are presented as 





Chapter 6 reports the results of a study focused on investigating the mutual 
relationship between resistin and the two major adipokines (i.e. adiponectin and 
leptin) and addressing the potential interaction between resistin and adiponectin on 
all-cause and CV mortality in a cohort of patients with kidney failure. 
Chapter 7 shows the results of an observational longitudinal study performed in a 
population-based cohort of elderly individuals (>65 years) from the Invecchiare in 
Chianti study and aimed at: 1) investigating the relationship between gamma-
glutamyltransferase (GGT), a multifaceted biomarker impinging upon oxidative stress, 
and all-cause and CV mortality; 2) assessing whether oxidized low-density lipoproteins 
(oxLDL), which co-localize with GGT in atherosclerotic plaques, modify the relationship 
between GGT and mortality. 
Chapter 8 presents a general discussion and alludes to future perspectives. 
Chapter 9 reports a compendium of the thesis. 
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Pro- and anti-inflammatory cytokine gene expression 
in subcutaneous and visceral fat in severe obesity 
Spoto B, Di Betta E, Mattace-Raso F, Sijbrands E, Vilardi A, Parlongo RM, Pizzini 
P, Pisano A, Vermi W, Testa A, Cutrupi S, D'Arrigo G, Lonardi S, Tripepi G, 
Cancarini G, Zoccali C. 
































Background and Aims: Pro-inflammatory molecules produced by adipose tissue have 
been implicated in the risk of cardiovascular (CV) disease in obesity. We investigated 
the expression profile of 19 pro-inflammatory and 7 anti-inflammatory genes in 
subcutaneous adipose tissue (SAT) and in visceral adipose tissue (VAT) in 44 severely 
obese individuals who underwent bariatric surgery. 
Methods and Results: SAT and VAT expressed an identical series of pro-inflammatory 
genes. Among these genes, twelve were significantly more expressed in SAT than in 
VAT while just one (IL18) was more expressed in VAT. The remaining genes were 
equally expressed. Among pro-inflammatory cytokines, both IL6 and IL8 were about 
20 times more intensively expressed in SAT than in VAT. The expression of nine genes 
was highly associated in SAT and VAT. Only for 3 pro-inflammatory cytokines (IL8, IL18, 
SAA1) in SAT the gene expression in adipose tissue associated with the circulating 
levels of the corresponding gene products while no such an association was found as 
for VAT. 
Conclusions: The expression of critical pro-inflammatory genes is substantially higher 
in SAT than in VAT in individuals with morbid obesity. The variability in circulating 
levels of pro-inflammatory cytokines is, in small part and just for three pro-
inflammatory cytokines, explained by underlying gene expression in SAT but not in 
VAT. 
These results point to a compartment-specific adipose tissue contribution to 
inflammation in obesity and indicate that abdominal SAT contributes more than VAT 











Adipose tissue is distributed throughout the body in discrete fat compartments which 
broadly cluster into two regions, a central and a peripheral one (1). The central region 
includes subcutaneous adipose tissue (SAT) of the thorax and the abdomen as well as 
intra-thoracic and intra-abdominal visceral adipose tissue (VAT), while peripheral fat 
consists of subcutaneous fat depots in the arms and the legs. The topography of 
adipose tissue accumulation is considered relevant for the risk of developing the 
metabolic and hemodynamic sequels of insulin resistance, including type 2 diabetes, 
dyslipidaemia and hypertension (2) but the issue remains controversial. Waist to hip 
circumference ratio, an established metric of abdominal obesity, consistently 
associates with hyperinsulinemia, glucose intolerance, type 2 diabetes, dyslipidaemia, 
hyperuricemia and cardiovascular disease (3). However, a large waist to hip ratio may 
encompass both increased SAT and VAT depots and therefore this metric does not 
allow a distinction of the underlying links of visceral and subcutaneous fat with 
hyperinsulinemia and attendant metabolic alterations. The issue is of relevance 
because VAT is generally held as the main determinant of metabolic risk (4) while SAT 
is considered either neutral or protective as for the same risk (5). In VAT, free fatty 
acids (FFA) generated by enhanced lipolysis directly augment lipid synthesis and 
gluconeogenesis in the liver thereby triggering insulin resistance, hypertension and 
atherosclerosclerotic complications (4). However, visceral fat is just a minor segment 
of total fat depots (less than 1/5 of whole body fat tissue) contributing to about 15% 
of the whole body FFA pool which is made up mainly by non-splanchnic adipose tissue 
(3, 6). 
Adipose tissue is also an abundant source of inflammatory cytokines and an excess of 
fat mass has been associated with a chronic subclinical inflammatory state (7). It is 
recognized that important differences exist in the gene expression profile of 
abdominal SAT and VAT (8-10) and that these two fat depots independently enhance 
the risk of CV complications (11). However, with respect to inflammatory genes, only 
few studies explored a large set of pro-inflammatory and anti-inflammatory cytokines 




(12, 13) and the results are controversial. Further studies encompassing multiple 
inflammatory genes in SAT and VAT are of obvious relevance to clarify the relative role 
of these two adipose tissue compartments in fat-dependent inflammatory 
mechanisms in human obesity. With this background in mind, we compared the 
expression profiles of 19 major pro-inflammatory and 7 anti-inflammatory genes in 
SAT and VAT in 44 severely obese individuals. 
 
SUBJECTS AND METHODS 
The protocol of the study was approved by the local ethical committee and all subjects 
gave informed, written consent to their participation into the study.  
Subjects 
The study population was recruited from the Division of General Surgery 1 of Brescia 
and included 44 incident obese patients who underwent bariatric surgery 
(biliopancreatic diversion in 11; gastric bypass in 10; mini-gastric bypass in 22; 
abdominal plastic in 1).  
Laboratory measurements 
Blood sampling was performed early in the morning after an overnight fast and plasma 
was stored at - 80°C until batch analyses. Serum glucose, cholesterol, triglycerides, 
albumin, haemoglobin, urea, uric acid, bilirubin, GOT, GPT, creatinine and C-reactive 
protein measurements were made using standard methods implemented in a 
multichannel analyser in the routine clinical laboratory. Insulin (MP Biomedicals, NY, 
USA) as well as adiponection and leptin (Linco Reasearch, USA) were measured by 
radioimmunoassay kits. Enzyme-linked immunosorbent assays (ELISA) were applied to 
measure plasma levels of IL1, IL6, TNF, IL18, resistin, PAI, VCAM1 (R&D Systems, 
Inc., Minneapolis, USA), IL8, SAA1 (Invitrogen, Carlsbad, CA, USA) and visfatin 
(Adipogen International, Inc., San Diego, USA).  
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated 
according the formula HOMA-IR=[fasting insulin concentration (U/mL) x fasting 




Adipose tissue sampling and gene expression analysis  
SAT and VAT from abdominal region was harvested at the beginning of surgical 
intervention and the adipose samples were collected in RNAlater (Ambion, Life 
Technologies, USA) and stored at -80°C until processing for RNA extraction. Total RNA 
was isolated from approximately 80-mg frozen SAT and VAT by means of the RNeasy 
Lipid Tissue Mini Kit (Qiagen Sciences, USA), according to the manufacturer’s 
instructions. Total RNA was treated with the DNA-free kit (Ambion, Austin, TX, USA) 
to digest contaminating genomic DNA. The concentration of the RNA samples was 
determined spectrophotometrically (NanoDrop ND-1000, Thermo Fisher Scientific 
Inc.). Single-stranded complementary DNA (cDNA) was synthesized using High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) 
following the manufacturer’s protocol. Pre-validated TaqMan Gene Expression Assays 
from Applied Biosystems were used to quantify the expression of pro-inflammatory 
genes (IL6, IL6R, IL8, CXCR1, CXCR2, TNF, IL1, IL1R1, TGF, MCP1, IL18, PAI, SAA1, 
TLR4, ICAM1, VCAM1, Visfatin, Resistin, Leptin) and anti-inflammatory genes (IL2, IL4, 
IL10, IL13, SOCS3, CD163, Adiponectin). The RT-PCR was performed by a 7300 Real 
Time PCR System (Applied Biosystems, Foster City, CA, USA). All genes were run in 
duplicate and negative controls were introduced in each plate. Target genes were 
considered unexpressed if the threshold cycle (Ct) value > 38. All values were 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GADPH) gene expression 
to correct for variation in RNA amounts and efficiency of reverse transcription. The 
relative quantification value of the target genes was calculated using the comparative 
Ct method, expressed as 2–[delta][delta]Ct (fold difference), and reported as arbitrary units 
(AU). 
Gene expression in pooled samples  
To preliminary test the gene expression of the 26 target genes, we performed a 
pooling analysis using a SAT and VAT pool. Each pool was built using an identical 
quantity of SAT and VAT mRNA from every patient. Pooled mRNA was reverse 
transcribed and the resulting cDNA was amplified. The gene expression of the target 




genes in the two pools was compared and only those differentially expressed in SAT 
and VAT were further analysed on individual basis. To identify differentially expressed 
target genes we adopted a conservative approach consisting of a difference in 
SAT/VAT gene expression ratio more than 50%. 
Histological analysis of adipose tissue samples 
SAT and VAT samples obtained from 14 patients were formalin-fixed and paraffin-
embedded. Four micron tissue sections were stained for hematoxylin and eosin and 
immunostained using a Bond MaxTM autostainer (Menarini Diagnostics, Florence, 
Italy). Standard immunoperoxidase staining protocols for CD45 - a pan-leukocyte 
antigen - (Clone RP2/18 and RP2/22,  Leica Microsystems, Newcastle upon Tyne, UK) 
and CD163 – an antigen for a macrophage subpopulation of major relevance for the 
anti-inflammatory response - (Clone 10D6, Thermo Scientific, Fremont, CA) were 
followed. In all the adipose tissue samples, cell automatic counting on CD163 stained 
sections was performed on digitalized slides (Aperio Scanscope, CA, USA) by analyzing 
the whole section using IHC Nuclear algorithm. Data were expressed as number of 
cells/cm2.  
Statistical analysis 
Data are expressed as mean ± SD (normally distributed data), median and inter-
quartile range (non-normally distributed data) or as percent frequency, as 
appropriate. Within groups comparisons were made by the Wilcoxon Rank test. The 
association between two continuous variables considered simultaneously was 
assessed by Pearson product moment correlation coefficients (r) and P values. 
Variables having a positively skewed distribution were log transformed (Ln) before the 
correlation study. The correlation coefficient was calculated with and without the 
exclusion of the outliers as identified by Mahalanobis distance test (14). The 
agreement between gene expression in VAT and SAT was investigated by calculating 
the shared variance (r2) of tested genes in visceral and subcutaneous fat.  Because our 
study focuses on a specific etiological hypothesis and on a strong a priori we did not 





In a previous paper in severe obese women (13), the ratio between SAT and VAT gene 
expression of a major inflammatory biomarker (IL6) was reported to be 3. With this 
background in mind, we calculated that by enrolling at least 44 obese individuals 
(including a 10% attrition rate) our study will achieve 80% power to detect as 
significant (alpha-error=0.01) a ratio >3 in IL6 gene expression between SAT and VAT. 
We assumed that the ratio in the gene expression between SAT and VAT of all 
inflammatory and anti-inflammatory molecules considered in the study was equal or 
greater of that calculated for IL6.  
 
RESULTS 
Demographic, somatometric and clinical characteristics of the patients 
Demographic, somatometric and clinical characteristics of the patients are reported 
in Table 1. 
The mean age of the patients was 41±9 years (11 M and 33 F). Obesity was of grade I 
(BMI ranging from 30.0 to 34.9 kg/m2) in 4 cases (9%), of grade 2 (BMI ranging from 
35.0 to 39.9 kg/m2) in 12 cases (27%) and of grade III in the remaining 28 cases (64%). 
The median value of glycemia was 99 mg/dL and only 4 were diabetic (3 on oral 
hypoglycemic drugs and 1 on insulin treatment). Serum cholesterol was on average 
199 mg/dL and was above the upper limit of the normal range (200 mg/dL) in 22 cases. 
Blood pressure (BP) was 127±8/79±8 mmHg. No patient had a BP exceeding 140/90 
mmHg and only 3 were on anti-hypertensive treatment (2 on mono-therapy with 
sartans or β-blockers or angiotensin-converting enzyme inhibitors and the remaining 
one on triple therapy with a β-blocker, an angiotensin-converting enzyme inhibitor 
and a diuretic). Six patients were habitual smokers. None of the patients was suffering 








Table 1. Main demographic, somatometric and clinical characteristics of the study patients 
 
   (n = 44) 
Age (years) 41±9 




Diabetics n. (%) 4 (9) 
Smokers n. (%) 6 (14) 
On-anti-hypertensive treatment n. (%) 3 (7) 
On anti-diabetics treatment n. (%) 4 (9) 
Systolic BP (mmHg) 127±8 
Diastolic BP (mmHg) 79±6 
Total cholesterol (mg/dL) 199±40 
Triglycerides (mg/dl)  121 (77-169) 
Haemoglobin (g/dL) 13.1±1.7 
Albumin (g/dL) 4.4±0.2 
Glucose (mmol/L) 99 (92-115) 
Insulin (µUI/mL) 37 (31-53) 
HOMA-IR (µU/mL*mmol/L) 1.26±0.8 
Azotemia (mg/dl) 33±7 
Uric acid (mg/dl) 5.6±1.6 
Total Bilirubin (mg/dl) 0.4 (0.3-0.7) 
GOT (UI/L) 16.5 (12.2-25.7) 
GPT (UI/L) 30.0 (21.2-44.0) 
CRP (mg/L) 6.4 (3.3-15.6) 
Creatinine (mg/dl) 0.69±0.15 
Data are expressed as mean± SD, median and inter-quartile 
range or as percent frequency, as appropriate 
 
Preliminary gene expression analysis in pooled samples 
From a total number of 26 cytokines tested in pooled samples (Figure 1), 13 genes 




SAA1, visfatin, resistin, leptin) and just one anti-inflammatory gene (adiponectin) 
resulted to be  differentially expressed in SAT compared with VAT. Ten genes were 
equally expressed (IL1R1, IL6R, IL10, TGFβ, MCP1, ICAM1, VCAM1, TLR4, SOCS3, 
CD163) in SAT and VAT and 3 anti-inflammatory genes were unexpressed (IL2, IL4 and 
IL13) in both fat compartments (Figure 1).  
 
Figure 1. Flowchart representing the process for analyzing pro and anti-inflammatory gene 




List of adipose tissue pro and anti-inflammatory genes tested 
Pro-inflammatory genes (n=19) 
IL1: Interleukin-1 beta; IL1R1: Interleukin 1 receptor; TNF: Tumor necrosis factor alpha; IL6: Interleukin 
6; IL6R: Interleukin 6 receptor; TGFTransforming growth factor beta; IL8: Interleukin 8; CXCR1: Interleukin 
8 receptor 1; CXCR2: Interleukin 8 receptor 2; IL18: Interleukin 18; MCP1: Monocyte chemoattractant 
protein 1; SAA1: Serum amyloid A1; TLR4: Toll-like receptor 4; ICAM1: Intercellular adhesion molecule 1; 
VCAM1: Vascular cell adhesion molecule 1; PAI: Plasminogen activator inhibitor; LEP: Leptin; RETN: Resistin; 
PBEF: Pre-B cell colony-enhancing factor/visfatin 
Anti-inflammatory genes (n=7) 
IL2: Interleukin 2; IL4: Interleukin 4; IL10: Interleukin 10; IL13: Interleukin 13; SOCS3: Suppressor of cytokine 
signaling 3; CD163: Cluster of differentiation 163; ADIPOQ: Adiponectin 
 
Gene expression analysis at individual level 
On the basis of findings in pooled samples, we undertook detailed analyses in 
individual patients. 




Among the 13 differentially expressed genes, adiponectin, leptin, resistin and visfatin 
gene expressions were from 1.6 to 5.1 fold higher in SAT than in VAT (Table 2) and this 
was also true for all, but one inflammatory cytokine (IL18) which, instead, was 12 fold 
more expressed in VAT (Table 2).  
 
Table 2. Gene expression measurements of pro and anti-inflammatory cytokines in paired 









Pro-inflammatory genes      
Tumor necrosis factor TNF  1.05 (0.71-1.57) 0.64 (0.36-1.20) 1.6 0.006 
Interleukin1  IL 1 0.46 (0.16-0.97) 0.09 (0.04-0.41) 5.1 0.001 
Interleukin 6 IL6 0.48 (0.06-1.00) 0.02 (0.003-0.325) 19.2 <0.001 
Interleukin 8 IL8 0.51 (0.14-0.99) 0.02 (0.003-0.305) 20.4 <0.001 
Interleukin 8 receptor, 
type 1 
CXCR1 0.23 (0.07-0.63) 0.05 (0.01-0.16) 4.6 <0.001 
Interleukin 8 receptor, 
type 2 
CXCR2 0.21 (0.10-0.83) 0.06 (0.01-0.20) 3.5 <0.001 
Interleukin 18 IL18 0.69 (0.50-1.03) 8.40 (3.50-15.20) 0.08 <0.001 
Serum amyloid A1 SAA1 1.00 (0.70-1.54) 0.63 (0.34-1.09) 1.6 0.03 
Plasminogen Activator 
Inhibitor  
PAI 1.07 (0.51-3.97) 0.31 (0.07-1.12) 3.5 <0.001 
Leptin LEP 0.77 (0.60-1.00) 0.24 (0.10-0.42) 3.2 <0.001 
Resistin RETN 0.71 (0.43-1.30) 0.25 (0.16-0.42) 2.8 <0.001 
Visfatin PBEF 0.51 (0.25-1.11) 0.10 (0.04-0.52) 5.1 <0.001 
Anti-inflammatory genes      
Adiponectin ADIPOQ 2.02 (1.19-3.13) 0.96 (0.58-1.76) 2.1 0.001 
Gene expression measurements (3rd and 4th columns) are expressed as arbitrary units and reported as 
median (inter-quartile range). The SAT/VAT ratio (5th column) represents the fold difference in cytokine 
gene expression measurements between SAT and VAT. In the last column the P value (Wilcoxon rank-sum 
test) of the difference between SAT and VAT gene expression measurements is also given. 
 
The expression of IL6 and IL8 genes was about 20 times higher in SAT than in VAT. Of 
note, the expression level of seven pro-inflammatory genes (IL1, IL6, IL8, CXCR1, 




P<0.001) in SAT and VAT while the remaining two genes (IL18 and PAI) showed much 
weaker associations (r2 =0.10 and r2 =0.12, respectively) (Figure 2). 
Figure 2. Correlation between cytokines gene expression in SAT and VAT. Gene expression 
measurements are expressed as arbitrary, Log-transformed units (Ln AU). Data are Pearson 
correlation coefficients (r), r2 and P value 
 
 
No relationship was found between SAT and VAT gene expression for the remaining 4 
genes (adiponectin, leptin, TNF and SAA1) (P>0.20). A separate analysis by gender 
fully confirmed these results (data not shown). 
Functional link between expression of pro- and anti-inflammatory genes and 
circulating molecules  
Eleven gene products (TNFIL1, IL6, IL8, IL18, SAA1, PAI, leptin, adiponectin, 
resistin, visfatin) were measured in plasma. Among these, only four inflammatory 
cytokines (IL8, IL18, SAA1, adiponectin) correlated with the corresponding gene 
expression in SAT or VAT. Plasma IL18 and SAA1 were directly related to the 
corresponding SAT gene expression while IL8 associated inversely with the 
corresponding gene expression (Figure 3). No relationship was observed between 
plasma levels of these three pro-inflammatory molecules and VAT gene expression of 
the corresponding genes (Figure 3). Among anti-inflammatory cytokines, only 




adiponectin gene expression in VAT showed an association with the corresponding 
gene product levels in plasma (Figure 3).  
 
Figure 3. Correlation between plasma levels of cytokines and the corresponding gene 
expression measurements in SAT or VAT. The arrows indicate the outliers identified by 
Mahalanobis distance test (see Ref. 14). The strength of these associations did not materially 
change after the inclusion of the outliers (all P≤0.02) 
 
 
Immune cells counting in SAT and VAT 
Given the specific involvement of immune cells in obesity-related inflammation, in a 
subgroup of 14 patients we counted CD163+ macrophages (a subpopulation of major 
relevance for the anti-inflammatory response) in SAT and VAT. We found that there 
was no difference in the number of CD163+ macrophages between SAT and VAT 
(3418±1353 n/cm2 vs 3732±1396 n/cm2, P=0.54), indicating that differences in the 
inflammatory status of the two fat compartments do not depend on the number of 
these cells.  
 
DISCUSSION 
In this study we quantified the gene expression of a large set of pro- and anti-
inflammatory cytokines in abdominal SAT and VAT in severe obesity. The vast majority 
of pro-inflammatory genes were more expressed in SAT than in VAT whereas just one 
pro-inflammatory gene was more expressed in VAT, suggesting a stronger 





Gene expression in SAT and VAT 
Central adiposity is more strongly associated with adverse CV outcomes than 
peripheral adiposity (3). Although this risk excess is traditionally attributed to visceral 
fat (4), the predominant component of fat mass in central adiposity is subcutaneous 
rather than visceral (16). 
We found that SAT and VAT express the same set of inflammatory cytokines in obese 
patients and that SAT, rather than VAT, is the fat compartment expressing the higher 
pro-inflammatory profile. This was true for fundamental fat cytokines like TNF and 
IL6, the expression levels of these cytokines being from 1.6 to 20-fold greater in this 
fat compartment than in VAT (Table 2). These findings accord with previous studies 
focusing on TNF and IL6 (10, 13, 17) and add weight to the contention that IL1 gene 
expression is upregulated (10, 13), rather than downregulated (18), in SAT of obese 
patients. Furthermore, for the first time we show that IL8 is upregulated in SAT and 
that the gene expression of this chemokine is more than 20 times higher in SAT than 
in VAT. Such a remarkable increase of IL8 mRNA in SAT was paralleled by a significant 
increase of the gene expression of its corresponding receptors, i.e. CXCR1 and CXCR2, 
in the same fat compartment (Table 2), further suggesting an augmented role for IL8 
signalling in SAT than in VAT in obese individuals. We also document an upregulated 
expression in SAT of other two important pro-inflammatory molecules like SAA1 
(Table 2) which is involved in early response to injury, and PAI which is responsible for 
the negative regulation of the fibrinolytic system. 
Leptin, Resistin and Visfatin are potent pro-inflammatory peptides. Consistently with 
previous studies (10, 12), we observed a 3-fold higher leptin and resistin gene 
expression in SAT. We found a similar pattern for visfatin, an insulin-mimetic peptide 
typically expressed in VAT. Of note, adiponectin, an anti-inflammatory cytokine, 
followed the same pattern, being twice more expressed in SAT than in VAT. IL18 was 
the sole pro-inflammatory cytokine showing a reverse expression pattern, being 
upregulated in the visceral rather than in the subcutaneous fat compartment. IL18 is 
a pleiotropic molecule promoting Th1 cell differentiation, cell-mediated cytotoxicity 




and inflammation which also induces the synthesis of the anti-inflammatory cytokine 
IL10 (19) and limits the release of chemokines such as IL8 (20). IL18-deficiency in mice 
causes hyperphagia, obesity, diabetes and atherosclerosis by massive fat deposition 
in the arterial walls (21). Thus, IL18 downregulation in SAT is in keeping with the 
hypothesis that the overall expression profile of cytokines in SAT denotes a more pro-
atherogenic, metabolically adverse attitude.  
Although in our study the expression of pro-inflammatory genes was systematically 
upregulated in SAT, we found a strong and positive correlation between SAT and VAT 
gene expression for the majority of the pro-inflammatory genes studied (i.e. IL1, IL6, 
IL18, IL8, CXCR1, CXCR2, resistin, visfatin and PAI) indicating that, though at different 
rates, the two main fat compartments undergo qualitatively similar changes in the 
expression profile of inflammatory cytokines.  
Monocytes/macrophages typically accumulate in adipose tissue and are primarily 
responsible for the release of inflammatory mediators in this tissue (13, 22). 
Macrophage infiltration is of comparable extent in SAT and VAT (23) and we show that 
the number of M2 macrophages, i.e. CD163+ macrophages with anti-inflammatory 
potential, is identical in SAT and in VAT suggesting that in obesity a higher 
transcriptional activity rather than an expansion of M2 macrophages pool explains the 
increased pro-inflammatory gene expression of subcutaneous fat compartment. 
Gene expression profile and circulating gene products 
Circulating levels of inflammatory cytokines like TNF (24), IL6 (25), IL8 (26), IL1 (27), 
IL18 (28), SAA1 (25), leptin (29) and resistin (30) are potent predictors of adverse 
cardiovascular outcomes. Adipose tissue cytokines mainly act as autacoids in the fat 
compartment. Interestingly, we found a strong association between adipose tissue 
gene expression and the corresponding plasma levels for 4 inflammatory cytokines 
(IL8, IL18, SAA1, adiponectin). Specifically, we found a positive correlation between 
SAT gene expression and plasma levels of IL18 and SAA1 and an inverse one in the 
same fat compartment between gene expression and plasma levels of IL8 (Figure 3). 




expression only in VAT (Figure 3). Overall these findings provide circumstantial 
evidence that the adipose tissue in vivo may contribute to regulate circulating levels 
of, at least, some cytokines.  
A potential limitation in our study is that because patients in this series had a low 
prevalence of diabetes and hypertension, selection bias cannot be excluded. 
In conclusion, we show compartment-specific adipose tissue changes in inflammation-
related genes in obesity and support the hypothesis that abdominal SAT contributes 
to the pro-inflammatory burden of severe obesity more than VAT, an observation also 
in keeping with the association of 3 pro-inflammatory cytokine genes with the 
corresponding gene product plasma levels. Whether the augmented pro-
inflammatory profile of SAT in obese patients predicts CV events warrant further 
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Background: Left ventricular hypertrophy (LVH) is a major cardiovascular (CV) 
complication in patients with kidney failure and an association between 
polymorphisms in the ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) 
gene, a genetic marker of insulin resistance, and LVH and LV concentric remodelling 
has been recently documented in these patients. 
Aims: Since myocardial fibrosis is a prominent feature in LVH induced by insulin 
resistance, we tested the hypothesis that the interaction between ENPP1 rs1974201 
and rs9402349 polymorphisms and the Tissue Inhibitor of Metalloproteinases (TIMP-
1) - a pro-fibrotic protein which inhibits extracellular matrix degradation - is implicated 
in concentric LVH and diastolic dysfunction in a cohort of 223 dialysis patients. 
Results: Both ENPP1 polymorphisms rs1974201 and rs9402349 were in Hardy-
Weinberg equilibrium in dialysis patients. In an analysis stratified by ENPP1 rs1974201 
polymorphism, circulating levels of TIMP-1 in GG patients were coherently associated 
with two markers of concentric remodelling (RWT and LV mass to volume ratio) as 
well as with a marker of diastolic dysfunction (E/A ratio) (P ranging from 0.005 to 0.02) 
whereas no such associations existed in CC or CG patients. These observations suggest 
that the rs1974201 modifies the relationship between TIMP-1 and LV geometry and 
diastolic dysfunction. Accordingly, in a multiple regression model, an identical increase 
of TIMP-1 (100 ng/ml) was associated with an increase of 22% in RWT, 14% in LV mass 
to volume ratio and 29% in E/A ratio in GG patients but with almost no change (from 
-0.22 to 3.78%) in these echocardiographic indices in the remaining patients (P for the 
effect modification <0.024). The rs9402349 did not modify the relationship between 
TIMP-1 and LV geometry and function. 
Conclusion: In dialysis patients, the ENPP1 rs1974201 polymorphism modifies the 
association between TIMP-1 and LV geometry and diastolic function. These results are 
consistent with the hypothesis that insulin resistance is involved not only in LVH but 






Left ventricular hypertrophy (LVH) is a pervasive complication of kidney failure and a 
strong predictor of death and adverse clinical outcomes in this population (1). From a 
structural point of view, cardiomyopathy in kidney failure is characterized by 
cardiomyocytes hypertrophy accompanied by prominent fibrosis. LV fibrosis depends 
on an altered balance between the accumulation and breakdown of cardiac 
extracellular matrix, a process regulated by matrix metalloproteinases (MMPs), a 
series of enzymes which are in turn inhibited by specific inhibitors [tissue inhibitors of 
metalloproteinases (TIMPs)]. Over-expression of TIMP-1 was observed in parallel with 
an increased LV mass in experimental models of pressure overload (2) and circulating 
levels of TIMP-1 were associated with LVH and LV diastolic impairment in individuals 
in the general population in the Framingham heart study (3) and in hypertensive 
patients as well (4-6). TIMP-1 is currently considered as a promising marker of 
myocardial fibrosis in cardiomyopathies (7, 8). 
The ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene is a well 
characterized genetic marker of insulin resistance since it codes for a membrane 
glycoprotein that inhibits insulin receptor autophosphorylation thus altering the 
intracellular insulin signalling (9). In a recent study, we have found that two 
polymorphisms (i.e. rs1974201 and rs9402349) in the ENPP1 gene are associated with 
myocardial hypertrophy and LV concentric remodelling in dialysis patients (10). Since 
there is coherent evidence that insulin resistance promotes myocardial fibrosis (11), 
we investigated the hypothesis that genetic markers of insulin resistance in this 
population modify the link between a prototypic, pro-fibrotic cytokine at myocardial 
level like TIMP-1 and LV mass and function. To this scope, we sought whether ENPP1 
gene and TIMP-1 levels interact in determining LV geometry and function in the same 
set of patients with kidney failure in which we described the association between the 
ENPP1 gene polymorphisms and LVH (10). 
 
 




SUBJECTS AND METHODS 
The study protocol was in conformity with the ethical guidelines of our institution and 
informed consent was obtained by each participant.  
Patients 
We studied an incident-prevalent cohort of 223 dialysis patients (125 males and 98 
females, all Caucasian) who had been on regular dialysis treatment for at least 6 
months, with left ventricular ejection fraction more than 35% and without cardiac 
circulatory congestion, major infections (fever, infected vascular access or peritonitis 
or exit site infection) or inter-current illnesses requiring hospitalization. One hundred 
and seventy-nine haemodialysis patients were being treated thrice weekly with 
standard bicarbonate dialysis (Na 138 mmol/L, HCO3 5 mmol/L, K 1.5 mmol/L, Ca 1.25 
mmol/L, Mg 0.75 mmol/L) either with Cuprophan or semi-synthetic membranes. The 
average urea Kt/V in these patients was 1.21+0.26. The remaining 44 patients were 
on chronic ambulatory peritoneal dialysis (CAPD) and the average weekly urea Kt/V 
was 1.67+0.32. Thirty-five patients were diabetics and 91 were habitual smokers 
(22±17 cigarettes/day). Ninety-five patients were treated with various anti-
hypertensive drugs (74 on mono-therapy with angiotensin-converting enzyme 
inhibitors, AT-1 antagonists, calcium channel blockers, - and β-blockers and the 
remaining 30 on double or triple therapy with various combinations of these drugs). 
One hundred and fifteen patients were on treatment with erythropoietin. The main 
clinical and biochemical characteristics of the study population are detailed in Table 
1.  
Genotyping of the ENPP1 rs1974201 and rs9402349 polymorphisms 
Allelic discrimination for the two single nucleotide polymorphisms (SNPs) of ENPP1 
gene, described under identification number rs1974201 and rs9402349, were 
performed by validated TaqMan SNP Genotyping Assays provided by Applied 
Biosystems on an ABI PRISM 7900HT Fast Real-Time PCR System, according to the 




previously reported (10). A random 10% of samples were independently repeated to 
confirm genotyping results and they were completely consistent.  
Laboratory measurements 
 Blood sampling was performed after an overnight fast always during a mid-week non-
dialysis day for haemodialysis patients and at empty abdomen for CAPD patients. 
Blood was drawn and put into tubes containing EDTA, and plasma supernatants were 
stored at –80°C until batch analyses. All analyses were done blinded to clinical 
information. Serum cholesterol, albumin, calcium, phosphate and haemoglobin 
measurements were made using standard methods in the routine clinical laboratory. 
Plasma total homocysteine, ADMA and high sensitivity C-Reactive Protein (CRP) were 
measured as previously reported (12). Circulating levels of TIMP-1 were measured by 
an ELISA with the use of a Quantikine kit (intra-assay CV: 4.4%; inter-assay CV: 4.2%; 
upper limit of the normal range: 304 ng/ml. R&D Systems Inc, MN, USA). 
Echocardiography  
These studies were performed in a non-dialysis day for hemodialysis patients or at 
empty abdomen for those on CAPD within 2 hours after blood sampling. Left 
ventricular mass (LVM) was calculated according to the Devereux formula and indexed 
to height2.7 (LVMI), as detailed in a previous study (13). Left ventricular hypertrophy 
(LVH) was defined by a LVMI of over 47 g/m2.7 in women or over 50 g/m2.7 in men. Left 
ventricular end diastolic volume (LVEDV) was calculated by the standard formula 
[(1.047*LVEDD3)/body surface area]. The relative wall thickness [RWT: 2*posterior 
wall thickness/left ventricular end diastolic diameter (LVEDD)] and the LV mass-to-
volume ratio, a ratio specifically applied in patients with kidney failure (14), were 
calculated as indexes of left ventricular concentric geometry. Values indicative of 
concentric left ventricular geometry were established on the basis of age-specific 
reference standards according to RWT (15). The ratio between early (E) and late (atrial 
- A) ventricular filling velocity (E/A ratio) was considered as an index of left ventricular 
diastolic function. 
 





Data were summarized as mean ± standard deviation (normally distributed data), 
median and inter-quartile range (non-normally distributed data) or as percent 
frequency and comparisons between to groups were made by T-test, Mann-Whitney 
U Test or Chi Square test, as appropriate.  
 The effect modification of ENPP1 rs1974201 and rs9402349 polymorphisms on the 
relationship between circulating levels of TIMP-1 and LV geometry was investigated 
by univariate and multivariate linear and logistic regression models. Into the final 
model, we included TIMP-1, ENPP1 polymorphism (rs1974201 and rs9402349) and 
their interaction term as well as all variables that were related (with P<0.05) to the 
exposures (TIMP-1 and ENPP1 polymorphisms) or to the study outcomes (RWT, LV 
mass-to-volume ratio and E/A ratio). By this strategy we constructed models of 
adequate statistical power (at least 10 patients for each variable into the models). The 
estimated raise in RWT, LV mass to volume ratio and E/A ratio corresponding to a fixed 
increase in TIMP-1 (100 ng/ml) was derived from crude and fully adjusted regression 
coefficients and expressed as percentage change (± standard error). In the logistic 
regression analysis, data were expressed as odds ratio (OR) and 95% confidence 
interval (CI) and P value.  
 Data analysis was performed by a standard statistical package (SPSS for Windows, 
Version 9.01, Chicago, Illinois, USA). 
 
RESULTS 
The ENPP1 rs1974201 and rs9402349 polymorphisms were not in linkage 
disequilibrium (D’=0.735, r2=0.203) and their genotypic distributions (CC: 13%; CG: 
42%; GG: 45% and AA: 71%; AC: 27%; CC: 2%) did not deviate from Hardy-Weinberg 






Demographic, clinical and biochemical characteristics of patients with kidney failure 
as characterized by the ENPP1 rs1974201 and rs9402349 polymorphisms 
The demographic and clinical characteristics of patients divided according to the 
ENPP1 rs1974201 genotypes are presented in Table 1.  
 
 Table 1. Main demographic, somatometric and clinical characteristics of the study population 
  
 ENPP1 (rs1974201) polymorphism 
 







Age (years) 59,4±15,8 60,9±14,7 0.47 
Male sex n. (%) 74 (60.2) 51 (51) 0.17 
    
Smokers n. (%) 52 (42.3) 39 (39) 0.62 
Diabetics n. (%) 16 (13) 19 (19) 0.22 
On anti-hypertensive treatment n. (%) 46 (37.4) 49(49) 0.08 
Dialysis vintage (months) 76,4±72,3 57,8±58,2 0.04 
With CV comorbidities n. (%) 59 (48) 47(47) 0.89 
    
Systolic pressure (mmHg) 130,7±22,5 136,9±21,7 0.04 
Diastolic pressure (mmHg) 74,6±12,5 75,8±11,9 0.47 
Heart rate (beats/min) 79,9±13,2 82,3±10,9 0.17 
    
BMI (kg/m2) 25,2±3,9 24,9±5 0.59 
Cholesterol (mg/dL) 205,6±53,4 211,4±57,3 0.44 
Haemoglobin (g/L) 10,9±1,8 10,5±2 0.10 
Albumin (g/L) 4±0,5 4±0,6 0.55 
Calcium *Phosphate (mMol2/L2) 4,4±1,1 4,5±1,3 0.52 
CRP (mg/L) 6,7 (3,4-16) 10,4 (1,7-4,3) 0,04 
ADMA (µMol/L) 2,8 (1,5-4,4) 3,06 (1,8-4,3) 0,67 
Homocysteine (µMol/L) 27,2 (20-38,1) 25,9 (20,2-46,47) 0,96 
    
TIMP-1 (ng/ml) 183,3 (158,7-214,7) 187,3 (168,8-217,8) 0,42 
Data are expressed as mean± SD, median and inter-quartile range or as percent frequency, as 
appropriate. Comparisons among the two groups were made by t test (continuous variables) or 
Chi-Square Test (dichotomic variables) and non parametric U di Mann-Whitney test  
 
GG homozygotes for this polymorphism had higher C reactive protein and systolic 
pressure and displayed a shorter dialysis vintage as compared to the group combining 
CG and CC genotypes. Moreover, GG patients tended to be more frequently treated 
with anti-hypertensive drugs (P=0.08). No differences were observed as for the 
remaining demographic, clinical or biochemical data (Table 1). The same analysis 
carried out for the rs9402349 polymorphism showed that AA patients had higher 




serum cholesterol (212±58 mg/dL versus 198±48 mg/dL, P=0.03) and were more 
frequently on anti-hypertensive treatment (47% versus 32%, P=0.024) as compared to 
the group combining AC and CC patients. The two groups did not significantly differ as 
for the remaining clinical or biochemical data. 
TIMP-1, ENPP1 rs1974201 and rs9402349 polymorphisms and echocardiographic 
indicators of LV remodeling  
One hundred and eighty-seven patients out of 223 (84%) displayed LVH at 
echocardiography. Concentric LV geometry was the most frequent pattern (45%) 
(concentric LVH in 85 cases and  concentric LV remodeling in 15 cases) followed by 
eccentric LVH (n=87) (39%).  In the whole study population, TIMP-1 was directly 
associated to E/A ratio (r=0.17, P=0.014) but unrelated to RWT and LV mass-to-volume 
ratio (r ranging from 0.098 to 0.116, P=NS). A separate analysis by ENPP1 rs1974201 
genotypes, showed that in GG patients, circulating levels of TIMP-1 directly related to 
RWT (r=0.25, P=0.01), LV mass-to-volume ratio (r=0.24, P=0.02) and E/A ratio (r=0.28, 
P=0.005) while no such an association existed in patients with CG or CC genotypes. In 
a similar analysis by rs9402349 genotypes, TIMP-1 correlated with E/A ratio (r=0.19, 
P=0.02) in AA patients while no other relationships were found between this 
biomarker and the other echocardiographic indices (P=NS).   
Effect modification by ENPP1 rs1974201 polymorphism of TIMP-1-LV geometry 
relationship 
On crude analysis, the ENPP1 rs1974201 polymorphism modified the relationship 
between circulating levels of TIMP-1 and echocardiographic indicators of LV 
remodeling and E/A ratio (Fig. 1).  
Indeed, in a regression analysis stratified according to genotypes, a 100 ng/ml increase 
in circulating levels of TIMP-1 was associated with a 22% increase in RWT, 14% in LV 
mass to volume ratio and 29% in E/A ratio in patients with GG genotype but with minor 
or no change in patients with CC or CG genotypes (RWT: -0.2%; LV mass to volume 
ratio: -1.0%; E/A ratio: +3.8%) (Table 2). Data adjustment for potential confounders 




Figure 1. Correlation analyses between circulating levels of TIMP-1 with RWT, LV mass-to-
volume ratio and E/A ratio separately in CC or CG patients versus GG patients. Data are Pearson 
product moment correlation coefficient (r) and P value. At the bottom of each couple of graphs, 




Table 2. Multiple linear regression analyses of the interaction between TIMP-1 and ENPP1 
rs1974201 for explaining RWT, LV mass to volume ratio and EA ratio. 
  Regression coefficients (% change), standard errors and P values 
Crude Adjusted* 





RWT -0.2±2.2 22.1±2.2 0.012 -0.7±2.2 22.1±2.2 0.019 
LV mass to 
volume ratio 
-1.0±3.6 14.5±3.6 0.012 
   -1.6±3.1  14.0±3.1 
0.024 
EA ratio 3.8±5.0 29.0±5.0 0.004  3.8±5.0     29.0±5.0 0.002 
* Model adjusted for: systolic blood pressure, age, anti-hypertensive treatment, smoking, ADMA, CRP and 
albumin (see Methods-Statistical Analysis for more details) 
 




Forcing diabetes, gender and CV comorbidities into the multivariate analyses, these 
covariates did not affect the strength of the relationships between TIMP-1 and RWT, 
LV mass to volume ratio and E/A ratio (data not shown). When a similar analysis was 
carried out for the ENPP1 rs9402349, the genotypes of this polymorphism did not 
significantly affect the association between TIMP-1 and the echocardiographic 
parameters (P=NS).  
ENPP1 rs1974201 polymorphism and TIMP-1 and the risk for LV concentric 
remodeling  
The prevalence of concentric LV geometry was significantly higher (P=0.006) in GG 
(55%) than in GC and CC patients (45%). Both on crude and fully adjusted logistic 
regression analyses (Table 3), an identical increase in circulating levels of TIMP-1 (100 
ng/ml) was associated with a higher risk for concentric LV geometry (P=0.02) in GG 
than  in CG and CC patients (Fig. 2) and this was also true for concentric LV hypertrophy 
[GG patients: adjusted OR (100 ng/ml increase in TIMP-1): 4.07, 95% CI: 1.32-12.52; 
CG and CC patients: adjusted OR (100 ng/ml increase TIMP-1): 1.09, 95% CI: 0.64-1.88) 
(P for the effect modification=0.039).  
 
Table 3. Multiple logistic regression analysis of the interaction between TIMP-1 and ENPP1 
rs1974201 for explaining concentric left ventricular geometry 
Variables 
Left ventricular concentric geometry 
Odds ratio (95% CI) and P  
Crude Adjusted 
TIMP-1 (100 ng/mL increase) 
ENPP1 rs1974201 (CC+CG=0; GG=1) 
TIMP-1 (100 ng/mL increase)*ENPP1 
rs1974201 (CC+CG=0; GG=1) interaction term 
 








Systolic blood pressure (1 mmHg)  1.00(0.99-1.02), P=0.73 
Age (1 year) 0.99(0.97-1.02), P=0.59 
Anti-hypertensive treatment (0=no; 1=yes) 1.80(0.96-3.50), P=0.07 
Smoking (0=no; 1=yes) 1.05(0.57-1.91), P=0.87 
ADMA (1µmol/L) 1.22(1.06-1.41), P=0.005 
CRP (1 mg/L) 0.99(0.98-1.01), P=0.61 
Albumin (1 g/dL) 0.98(0.92-1.03), P=0.48 






Figure 2.  Effect modification of ENPP1 rs1974201 polymorphism on the crude and adjusted 
odds ratio for left ventricular concentric geometry corresponding to a fixed increase in TIMP-1 
(100 ng/ml) in patients with and without GG genotype. Data are expressed as odds ratio and 




This study shows that in dialysis patients the rs1974201 polymorphism in the ENPP1 
gene, a genetic marker of insulin resistance in this population, modifies the 
relationship between TIMP-1 and left ventricular geometry and diastolic function. 
These findings are in line with the hypothesis that fibrosis is an important component 
in LV remodeling and hypertrophy triggered by insulin resistance in this population. 
In close parallelism with studies in the remnant kidney model (16), postmortem 
studies in patients with kidney failure have coherently shown that LVH and structural 
remodeling of myocardium is characterized by hypertrophy of cardiomyocytes 
accompanied by an abnormal accumulation of fibrous tissue in the interstitium of the 
myocardium (17). Furthermore, ultrasonic myocardial characterization studies in vivo 
in patients with kidney failure (18, 19) confirmed that fibrosis is a hallmark in LVH in 
dialysis patients. Myocardial fibrosis, in the setting of LVH, is not unique to kidney 
failure and may occur in several conditions including hypertension (20), 
hyperaldosteronism (21, 22) and hyperinsulinemia and insulin resistance (23). As a 




matter of fact, insulin sensitivity as measured by whole body glucose disposal explains 
the 19% of the variability in the muscular component of the LV in essential 
hypertensives (24). The causal implication of insulin resistance in LVH in these patients 
is also supported by the observation that regression of myocardial hypertrophy goes 
strictly along with improvement in insulin resistance in longitudinal studies (25). 
Excess of collagen at myocardial level results from a derangement in the dynamic 
balance between collagen synthesis by cardiac fibroblasts and collagen degradation 
by matrix metalloproteinases (MMPs). The proteolytic activity of MMPs is regulated 
by tissue inhibitors of metalloproteinases (TIMPs), particularly by TIMP-1 (26), and an 
unbalanced relationship between TIMP-1 and MMPs results in myocardial fibrosis. 
Indeed, in spontaneously hypertensive rats (SHRs), increased myocardial expression 
of TIMP-1 largely explains the diminished collagenase activity and excess fibrosis in 
this experimental model (2). Coherently with animal studies, it was demonstrated that 
plasma TIMP-1 is a marker of LVH and myocardial fibrosis both in individuals in the 
general population (3) and in essential hypertensives (4-6). Of note, MMP/TIMP 
balance is affected by insulin because this hormone shifts this balance toward 
reduction of extracellular matrix degradation via the phosphatidylinositol 3-kinase (PI 
3-kinase)/protein kinase Akt pathway (27, 28).   
We have recently described that two polymorphisms (i.e. rs1974201 and rs9402349) 
in the ENPP1 gene which associate with myocardial hypertrophy and LV concentric 
remodeling in dialysis patients (10). Of note, in that study the rs1974201 
polymorphism, but not the rs9402349 polymorphism, showed also a parallel 
association with insulin and glucose levels (10). Because excess of fibrosis is a hallmark 
of concentric LVH in kidney failure, it appears possible that gene polymorphisms 
conducive to insulin resistance also modify the link between TIMP-1, a pro-
hypertrophic and pro-fibrotic compound, and LVH geometry and function. In line with 
this hypothesis, we found that ESRD patients homozygous for the G allele of the ENPP1 
rs1974201 polymorphism - precisely the same polymorphism showing a link with LVMI 




echocardiographic indices of LV geometry (RWT, LV mass-to-volume ratio) as well as 
with a fundamental marker of diastolic dysfunction like the E/A ratio. Thus, the ENPP1 
rs1974201 predisposes not only to concentric remodeling but also to a pro-fibrotic 
response to TIMP-1. The functional relevance of this relationship is underlined by the 
inverse association between TIMP-1 and E/A ratio in GG homozygous patients 
implying progressively more severe diastolic dysfunction at increasing TIMP-1 levels 
in these patients. These findings may have clinical implications because altered 
diastolic function is a death predictor in kidney failure (29, 30).  
Our study is limited in many respects. The first and the most obvious limitation is 
sample size. To avoid reporting false positive associations, large sample size and 
confirmatory analyses in diverse populations are recommended for testing genetic 
effects. However, it is important noting that the hypothesis we probed here was 
tested in an ethnically homogeneous cohort and had a strong “a priori” based on the 
previous association between concentric LV remodeling and ENPP1 gene variants in 
the same cohort (10). Furthermore, our study had also a precise biological rationale 
because insulin reduces collagen degradation by affecting the MMP/TIMP balance 
(26). Second, the cross-sectional design of the study precludes the possibility to draw 
definitive conclusions about the nature (causal/not causal) of the relationships we 
found. Third, we chose to measure plasma TIMP-1 because experimental data support 
a more important role of this enzyme compared to other tissue inhibitors of 
metalloproteinases, but we measured neither other TIMPs nor metalloproteinases.  
In conclusion, in a sizable series of dialysis patients, we show that the genetic 
variability in the ENPP1 gene, a major modulator of insulin sensitivity, modifies the 
relationship between the pro-fibrotic enzyme TIMP-1 and LV geometry and function. 
These data further support the concept that ENPP1 gene is a relevant player in the 
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Background and objectives: High serum interleukin-6 (IL-6) is a major risk factor for 
cardiovascular disease (CVD) in the general population. This cytokine is substantially 
increased in chronic kidney disease (CKD) patients but it is still unknown whether the 
link between IL-6 and CVD in CKD is causal in nature.  
Design, setting, participants and measurements: In a cohort of 755 stage 2-5 CKD 
patients, consecutively recruited from 22 Nephrology Units in Southern Italy, we 
studied the relationship of serum IL-6 with history of CVD as well as with incident 
cardiovascular (CV) events (follow up: 31±10 months) and used the functional 
polymorphism (-174 G/C) in the promoter of the IL-6 gene to investigate whether the 
IL-6-CV events link is causal in nature.   
Results: In adjusted analyses, serum IL-6 above the median value was associated with 
history of CVD (P<0.001) and predicted the incidence rate of CV events (HR:1.66, 
95%CI:1.11-2.49; P=0.01).  
Patients homozygous for the risk allele (C) of the -174 G/C polymorphism had higher 
levels of IL-6 than those with other genotypes (P=0.04). Homozygous CC patients had 
more frequently history of CVD (OR:2.15, 95%CI:1.15-4.00; P=0.02) as well as a 87% 
higher rate of incident CV events (HR:1.87, 95%CI:1.02-3.44; P= 0.04) as compared to 
other genotypes. 
Conclusions: In stage 2-5 CKD patients, high serum IL-6 is associated with history of 
CVD and predicts incident CV events. The parallel relationship with history of CVD and 
incident CV events of the -174 G/C polymorphism in the IL-6 gene suggests that IL-6 











Classical experimental studies by Russel Ross et al. in the nineties solidly established 
inflammation as a critical component of the atherosclerosis process (1). Over the last 
two decades, large cohort studies in the general population have shown strong links 
between biomarkers of inflammation and cardiovascular (CV) outcomes in the general 
population (2-5) and in patients with cardiovascular disease (CVD) (6, 7). 
Observational studies are methodologically vulnerable to test causality because these 
studies are open to various sources of bias and confounding. Mendelian 
randomization – i.e. the random assortment of alleles at conception – offers an 
intriguing opportunity to limit problems inherent to observational studies because 
categorization of patients according to pertinent alleles is a sort of genetic 
randomization. Genetic variants may thus be used as indicators of environmental 
exposures in the observational context (8). Large scale Mendelian randomization 
studies applying genetic polymorphisms of inflammatory cytokines (9) offer strong 
support to the hypothesis that, like in experimental animals (10, 11), the link between 
inflammation and atherosclerosis complication is causal in nature. 
Cardiovascular risk is a multifactorial problem in CKD patients (12).  Systemic 
inflammation is common in CKD patients, particularly in stage 5 CKD patients on 
dialysis (13, 14). In line with studies in the general population (5, 15), IL-6, a major pro-
inflammatory cytokine, is an established strong predictor of adverse clinical outcomes 
in stage 5D CKD patients (16-20). However, the relationship between IL-6 and CV 
disease at earlier CKD stages was investigated in just one relatively small study by 
Barreto et al. (21) which was based on a limited number of CV events (just 22 events). 
In addition, to date we lack specific proof that this relationship in the CKD population 
is causal in nature. Circulating levels of IL-6 are genetically regulated. 
Since transmission of genes is a random phenomenon, gene 
polymorphisms modulating IL-6 synthesis may represent an unbiased means for 
testing whether the link between IL-6 and CV outcomes in CKD patients is causal in 
nature (Mendelian randomization). The -174 G/C single nucleotide polymorphism is a 
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functional variant located in the promoter region of the IL-6 gene which regulates the 
rate of IL-6 gene transcription (22-28) and therefore represents a reliable research tool 
for testing the nature (causal vs non causal) of the link between IL-6 and CV outcomes 
in CKD. With this background in mind, we set out to confirm findings by Barreto et al. 
(21) in a large observational study including a carefully characterized cohort of 755 
stage 2-5 CKD patients and to test whether this relationship may underlie a causal link 
by applying the Mendelian Randomization approach i.e. by stratifying the study 




The study protocol was in conformity with the ethical guidelines of our institution and 
it was approved by ethical committees of all participating Units. Written informed 
consent was obtained from each participant.  
CKD patients 
Our study population included a genetically homogenous series of 755 Caucasian 
patients belonging to the same geographical area (Southern Italy) (29), consecutively 
recruited from 22 Nephrology Units in a period extending from October 2005 to 
September 2008. Eligible patients were age 18 to 75 years and in stable clinical 
condition. Exclusion criteria included acute or rapidly evolving renal disease, kidney 
transplant, acute inter-current infections or acute inflammatory processes, 
pregnancy, cancer or diseases in the terminal phase. This cohort was described in 
detail elsewhere (30). 
Control population 
To compare the allelic frequencies of the -174 G/C polymorphism observed in CKD 
patients, we studied a sample of 463 consecutive blood donors of the general 






Follow-up and study outcome  
After the initial assessment, patients were monitored for 31±10 months (range: 0.3 to 
48 months). The study end-point was fatal and non-fatal cardiovascular events as 
described elsewhere (30). These events included myocardial infarction documented 
by ECG and biomarkers of myocardial injury; heart failure defined as dyspnea in 
addition to two of the following conditions: raised jugular pressure, bi-basilar crackles, 
pulmonary venous hypertension or interstitial edema on chest x-ray requiring 
hospitalization; ECG documented arrhythmia; stroke; peripheral vascular disease; 
major arterial or venous thrombotic episodes. These events were accurately recorded 
during the follow-up period.  
The history of CVD was defined as the presence of at least one of the following 
comorbidities at enrolment: myocardial infarction, heart failure, peripheral vascular 
disease, stroke, transient ischemic attack or coronary surgery/angioplasty. 
Laboratory measurements 
In the whole study population blood sampling was performed in the early morning 
after an overnight fast and plasma was stored at - 80°C until analysis. Serum glucose, 
lipids, hemoglobin, albumin, creatinine and C-reactive Protein (CRP) were measured 
by standard methods in the routine clinical laboratory. Serum IL-6 was measured by 
enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Inc., Minneapolis, USA). 
Estimated glomerular filtration rate (eGFR) was calculated by using the 4-variables 
MDRD study equation (31) and not by CKD-EPI formula since the creatinine data were 
not IDMS traceable during the study period. All CKD patients underwent a 24h urinary 
collection for the measurement of proteinuria.  
Genotyping of -174G/C polymorphism 
Allelic discrimination of -174 G/C polymorphism was performed using a custom 
TaqMan SNP Genotyping Assay provided by Applied Biosystems (Applied Biosystems, 
Foster City, CA, USA). In this assay, primers were designed to amplify a region including 
the mutation site specifically recognized by a couple of probes able to discriminate 
wild-type and mutated alleles. The sequences of primers and probes were: 5’-
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CGACCTAAGCTGCACTTTTCC-3’ (forward primer) and 5’-
GGGCTGATTGGAAACCTTATTAAGATTG-3’ (reverse primer); 5’-
CCTTTAGCAT[G]GCAAGAC-3’ (C allele-specific probe) and 5’- 
CCTTTAGCAT[C]GCAAGAC-3’ (G allele-specific probe). Allelic discrimination was 
performed on a 7900HT Fast Real-Time PCR platform and its accompanying Sequence 
Detection System (SDS) Software version 2.4 (Applied Biosystems, Foster City, CA, 
USA). Briefly, genomic DNA was extracted from peripheral blood mononuclear cells 
using standard salting out procedure (32). The reaction system contained 20 ng of 
genomic DNA, 12.5 l of 2 X TaqMan Universal PCR Master Mix No AmpErase UNG, 
1,25 l of 40 X Assay Mix (including unlabeled PCR primers, FAM and VIC dye-labeled 
TaqMan MGB probes) and H2O for a total volume of 25 l. A random 10% of samples 
were independently repeated to confirm genotyping results. The genotype results for 
these samples were completely consistent. All analyses were done blinded to clinical 
information. 
Statistical analysis  
Data were expressed as mean ± standard deviation (SD), median and inter-quartile 
range (IQR) or as percent frequency and comparison between two groups were made 
by T Test, Mann-Whitney Test or Chi Square test, as appropriate. The comparison 
among more than two groups was performed by ANOVA for log transformed variables, 
when appropriate. The deviation from Hardy-Weinberg equilibrium was assessed by 
the Chi Square test comparing observed and expected genotype frequencies. The 95% 
confidence interval of the risk allele frequency was calculated as suggested by the 
standard method (33).  
The functional form of serum IL6 (as continuous, binary, quartiles or quintiles data) 
was formally investigated by the analysis of Martingale residuals and the binary form 
(below/above the median) provided the best data fitting.  
The relationships between serum levels of IL-6 and cardiovascular disease was 
performed by two approaches. First, we analyzed the baseline association between 




IL-6 in the prospective cohort study. In both logistic and survival analyses, we 
considered variables which met criteria to be confounders [i.e. variables related 
(P<0.10) to both the exposure under investigation (serum IL-6 levels below/above the 
median value) and history of CVD or incident fatal and non-fatal CV events, which are 
not an effect of the exposure and are not in the causal pathway between the exposure 
and outcome)] (34). Tested covariates included traditional risk factors (age, gender, 
smoking, diabetes and glucose, cholesterol and blood pressure), factors peculiar to 
CKD (hemoglobin, albumin, eGFR and urinary protein), anti-hypertensive treatment, 
BMI and C-reactive protein. In both logistic and Cox regression models, eGFR was 
always forced because of the strong and significant correlation between eGFR and 
serum IL-6 (Table 1a). To further investigate the causal role of IL-6 in the pathway 
leading to CV events in CKD patients, we applied a Mendelian randomization 
approach, i.e. we stratified the study population according to the -174 G/C 
polymorphism. These analyses were appropriately adjusted for variables which 
differed between CC and GC or GG patients and which appeared to be potential 
confounders (i.e. age, gender, cholesterol) for the interpretation of the link between 
the risk genotype (CC) and the study outcomes.   
In the prospective cohort study, the potential distortion on the study results due to 
the competing risks of death was assessed by comparing the incidence rate of death 
in exposed (high IL-6 levels or CC risk genotype) and unexposed patients (low IL-6 
levels or GC/GG genotype). If a difference was found, the competing risk of death was 
accounted by carrying out a survival analysis considering a combined outcome 
“death/CV events” (35). Data were expressed as odds ratio (logistic regression 
analysis), hazard ratio (Cox regression model), 95% confidence interval (CI) and P 
value. To internally validate the independent relationships of serum IL-6 and -174 G/C 
polymorphisms with history of CVD and incident CV events, a bootstrap resampling 
technique of 1,000 samples (randomly extracted from the original sample) was 
performed (36). All potential effect modifications exerted by covariates on the 
relationship between the key exposures (serum IL-6 and -174 G/C polymorphism) and 
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study outcomes were formally tested by introducing a multiplicative term into the 
models and no significant interaction was found.  
All calculations were made by using a standard statistical package (IBM SPSS Statistics 
for Windows, Version 21.0. 0.1, Armonk, NY: IBM Corp.).  
 
RESULTS 
We studied 755 patients with stages 2-5 CKD (stage 2: 3.0%; stage 3a: 22.0%; stage 
3b: 38.0%; stage 4: 34%, stage 5: 3.0%). Four hundred and fifty-three patients were 
males (60%), 263 were patients with type-2 diabetes, 98 were current smokers (13%). 
Two-hundred and twenty-one patients (29%) had history of CVD (Table 1a). One 
hundred and nine had only one past CV event while 112 of them had two or more than 
two past CV events. The first CV event in this population was myocardial infarction in 
19 cases, heart failure in 26 cases, peripheral vascular disease in 29 cases, stroke in 12 
cases, transient ischemic attack in 12 cases and coronary surgery/angioplasty in 11 
patients. Six hundred ninety-one (92%) were on antihypertensive treatment: 19% 
were treated with one medication, 29% with two medications, 28% with three 
medications and the 16% with four or more medications. Estimated GFR was on 
average 36±13 ml/min/1.73 m2 and the median 24h urinary protein was 0.6 mg/24h 
(inter-quartile range: 0.2-1.5 mg/24h). The median IL-6 was 2.5 pg/ml (inter-quartile 
range: 1.6-4.0 pg/ml).  
 
Analyses based on serum IL-6 levels  
Patients with IL-6 above the median value were significantly older, more frequently 
diabetics and had higher serum glucose and 24h urinary protein than those with IL-6 
below this threshold (Table 1). Estimated GFR, hemoglobin and albumin were lower 
in patients with higher IL-6 as compared with those with IL-6 below the median value. 
Systolic blood pressure (BP) was higher and diastolic BP lower in patients with IL-6 





Table 1 a. Main demographic and clinical characteristics of the study population according to 




Serum IL-6 <2.5 
pg/mL 
(n=380) 




Age (years) 62±11 59±12 64±9 <0.001 
Males (%) 453 (60) 224 (59) 229 (61) 0.55 
Diabetes (%) 263 (35) 105 (28) 158 (42) <0.001 
Current Smokers (%) 98 (13) 55 (14) 43 (11) 0.22 
CV comorbidities (%) 221 (29) 82 (22) 139 (37) <0.001 
     
BMI (kg/m2) 28.2±4.7 27.3±4.3 29.0±4.8 <0.001 
Systolic BP (mmHg) 134±18 132±17 135±19 0.03 




341 (90) 350 (93) 
0.89 
     
Glucose (mg/dL) 116±49 109±41 122±56 <0.001 
Total cholesterol (mg/dL) 187±45 189±43 184±46 0.12 
Hemoglobin (g/dL) 12.8±1.8 13.1±1.8 12.6±1.8 <0.001 
Albumin (g/dL) 4.2±0.5 4.2±0.5 4.1±0.5 0.01 
CRP (mg/L) 2.4  (1.0-5.5) 1.4  (0.7-2.8) 4.3  (1.9-9.0) <0.001 
Phosphate (mg/dL) 3.7±0.8 3.6±0.7 3.8±0.8 0.02 
eGFR (ml/min/1.73m2) 36±13 38±13 34±13 <0.001 
Urinary protein (g/24h) 0.6 (0.2-1.5) 0.5 (0.2-1 .2) 0.6 (0.2-1.7) 0.01 
Data are expressed as mean ±standard deviation, median and inter-quartile range and as percent 
frequency, as appropriate. 




As expected, serum CRP levels were directly associated with IL-6 levels (r=0.57, 
P<0.001). On bivariate, multivariate and bootstrapping validation analyses, patients 
with IL-6 above the median were more likely to have had a history of CVD (P<0.01) 
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Table 2.  Logistic regression models of history of CVD 
 
 Bivariate  Multivariate  Bootstrapping validation 
 
 OR (CI 95%)              P   OR (CI 95%)                   P      OR (CI 95%)             P  
*Serum IL-6  




<0.001 1.58 (1.11-2.24) 0.01 1.58 (1.12-2.24) 0.01 
Age  
(years) 
  1.05 (1.03-1.07) <0.001 1.05 (1.03-1.07) <0.001 
Diabetes  
(0=no; 1=yes) 
  2.83 (1.99-4.03) <0.001 2.83 (1.97-4.08) <0.001 
Systolic BP 
(mmHg) 
  1.00 (0.99-1.01) 0.93 1.00 (0.99-1.01) 0.94 
Haemoglobin 
(g/dL) 
  1.04 (0.94-1.16) 0.47 1.04 (0.93-1.16) 0.49 
Albumin  
(g/dL) 
  0.74 (0.50-1.11) 0.15 0.74 (0.50-1.11) 0.14 
Phosphate 
(mg/dL) 
  1.02 (0.80-1.30) 0.86 1.02 (0.78-1.34) 0.87 
Urinary protein 
(mg/24h) 
  1.01 (0.89-1.13) 0.93 1.01 (0.88-1.14) 0.93 
eGFR 
(ml/min/1.73m2) 
  1.00 (0.98-1.01) 0.57 1.00 (0.98-1.01) 0.57 
*Below/above the median value (in parenthesis). The description of the model building strategy is reported in 
the Method section.  
   Abbreviations: eGFR: estimated glomerular filtration rate. 
 
During the follow-up, 42 patients died. The incidence rate of mortality was 3 times 
higher (P=0.01) in patients with IL-6 above the median (3 deaths per 100 person-years, 
95% CI: 2.0-4.1) than in those with IL-6 below this threshold (1 death per 100 person-
years, 95% CI: 0.6-2.1). Overall, 117 patients had fatal and non-fatal CV events. As 
shown in Table 3, on bivariate, multivariate and bootstrapping validation analyses, the 
incidence rate of fatal and non-fatal CV outcomes was significantly higher (P<0.02) in 
patients with IL-6 above the median (8.6 CV events per 100 person-years, 95% CI: 2.5-
5.0) than in those with IL-6 below this threshold (3.6 CV events per 100 person-years, 







Table 3.  Cox regression models of incident CV events 
 Bivariate  Multivariate  Bootstrapping validation 
  
  HR (CI 95%)           P     HR (CI 95%)               P      HR (CI 95%)             P  
*Serum IL-6  




<0.001 1.66 (1.11-2.49) 0.01 1.66 (1.10-2.52) 0.02 
Age 
(years) 
  1.07 (1.04-1.10) <0.001 1.07 (1.03-1.10) <0.001 
Diabetes 
(0=no; 1=yes) 
  1.59 (1.09-2.32) 0.02 1.59 (1.06-2.37) 0.02 
Systolic BP  
(mmHg) 
  1.00 (1.00-1.02) 0.31 1.00 (1.00-1.02) 0.31 
Haemoglobin  
(g/dL) 
  0.91 (0.80-1.02) 0.10 0.91 (0.81-1.02) 0.09 
Albumin 
(g/dL) 
  0.82 (0.53-1.27) 0.38 0.82 (0.52-1.29) 0.39 
Phosphate  
(mg/dL) 
  1.13 (0.88-1.44) 0.34 1.13 (0.88-1.45) 0.35 
Urinary protein 
(mg/24h) 
  1.05 (0.94-1.17) 0.38 1.05 (0.93-1.18) 0.44 
eGFR  
(ml/min/1.73m2) 
  1.01 (0.99-1.02) 0.44 1.01 (0.99-1.02) 0.49 
*Below/above the median value (in parenthesis). The description of the model building strategy is 
reported in the Method section. 
 Abbreviation:  eGFR: estimated glomerular filtration rate 
. 
 
Figure 1. Serum levels of IL-6 (left panel) and C reactive protein (right panel) according to -174 
G/C polymorphism in IL-6 gene. Data are expressed as medians. The inter-quartile ranges are 
indicated in parentheses. The comparison among groups was made by ANOVA 
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CKD stages did not modify the IL6-CV risk relationship (P for interaction=0.33). Further 
analyses investigating IL-6 as a continuous variable confirmed this biomarker as a 
strong and independent risk factor for study outcomes [History of CVD, bivariate 
analysis OR (1 pg/mL): 1.16, 95% CI: 1.10-1.26, P<0.001;   multivariate analysis OR: 
1.10, 95% CI: 1.02-1.20, P=0.02; Incident CV events, bivariate analysis HR (1 pg/mL): 
1.14, 95%CI: 1.07-1.22, P<0.001; multivariate analysis HR: 1.12, 95% CI: 1.03-1.22, 
P=0.007]. 
To account for the potential effect of competing risks due to death on the IL6-CV 
outcomes relationship, an additional adjusted analysis by considering a combined 
end-point death/CV events was performed. This multivariate analysis showed that the 
hazard ratio of the combined end point was about 1.5 times higher (HR:1.54, 95% 
CI:1.05-2.26, P=0.03) in patients with IL-6 levels above the median as compared with 
the remaining ones.  
 
Analyses based on the -174 G/C polymorphism   
In CKD patients, the genotype distribution of -174 G/C polymorphism [GG, n=333 
(44%); GC, n=370 (49%); CC n=52 (7%)] significantly deviated from Hardy-Weinberg 
Equilibrium (2=14.3, P=0.001) while this was not true in healthy subjects [GG, n=277 
(60%); GC, n=170 (37%); CC n=16 (3%)] (2=2.70, P=0.10). Of note, the frequency of 
the C risk allele was significantly higher (P<0.02) in CKD patients (31%, 95% CI: 28-34%) 
than in healthy study participants (22%, 95% CI: 18-26%).  
CKD patients with CC genotype had higher levels of IL-6 (median:2.9 pg/ml, inter-
quartile range:1.7-6.9 pg/ml) than those with GC (2.4 pg/ml, 1.6-3.8 pg/ml) and GG 
(2.5 pg/ml, 1.7-4.0 pg/ml) (P=0.04) (Figure 2, left panel) and this was also true for CRP 
(CC, median: 3.2 mg/L, IQR: 1.2-10.4 mg/L; GC, 2.2 mg/L, 1.0-5.6 mg/L; GG, 2.4 mg/L, 
1.0-5.1 mg/L) (P=0.03) (Figure 2, right panel).  
These findings show that the relationship between -174 G/C polymorphism and 




genotype versus GC/GG genotypes). For this reason, further data analysis was carried 
out by using the recessive model. 
 
 
Figure 2. Serum levels of IL-6 (left panel) and C reactive protein (right panel) according to -
174 G/C polymorphism in IL-6 gene. Data are expressed as medians. The inter-quartile 
ranges are indicated in parentheses. The comparison among groups was made by ANOVA 
 
As shown in Table 4 and as expected from Mendelian randomization, CC patients 
versus GC/GG patients did not differ as for demographic and clinical 
characteristics except for a slight excess of males (75% versus 59%, P=0.02) in CC 
patients and slightly lower cholesterol levels (173±43 mg/dl versus 188±45 mg/dL, 
P=0.02) in patients with the same genotype. 
The prevalence of the history of CVD was higher in CC patients (44%) than in 
GC/GG patients (28%) (P=0.01). The odds ratio for this outcome was more than 
twice higher in patients harboring the CC risk genotype (odds ratio: 2.15, 95% 
CI:1.15-4.00; P=0.02) than in those with other genotypes in a model adjusting for 
age, gender and cholesterol, i.e. the covariates which differed (P<0.10) between 
patients with CC and GC/GG genotypes (see Table 4). A bootstrapping validation 
model confirmed these results (odds ratio: 2.14, 95% CI:1.18-3.89; P=0.01). 
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Table 4. Main demographic and clinical characteristics of the study population according to -174 
G/C polymorphism 
Data are expressed as mean ±standard deviation, median and inter-quartile range and 
as percent frequency, as appropriate. 




In the cohort study, the incidence rate of mortality did not differ between patients 
with and without the CC risk genotype (P=0.27) indicating that the competing risk of 
death on the -174 G/C polymorphism-CV events link could be excluded. In close 
parallelism with the strong association between serum IL-6 levels and CV events, the 
incidence rate of CV outcomes in patients with CC genotype was by the 87% higher 
(HR:1.87, 95% CI:1.02-3.44; P=0.04) than in those with the GC or GG genotypes (Figure 
1, right panel) and this was also true in a bootstrapping validation model (HR:1.87, 









Age (years) 59±13 62±10 0.09 
Males (%) 39 (75) 414 (59) 0.02 
Diabetes (%) 21 (40) 242 (34) 0.38 
Current Smokers (%) 9  (17) 89 (13) 0.34 
CV comorbidities (%) 23 (44) 198 (28) 0.01 
    
BMI (kg/m2) 27.9±3.8 28.2±4.7 0.54 
Systolic BP (mmHg) 132±16 134±18 0.41 
Diastolic BP (mmHg) 76±10 78±10 0.15 
On anti-hypertensive treatment 
(%) 
44 (85) 
647 (92) 0.69 
    
Glucose (mg/dL) 98 (87-127) 99 (88-120) 0.65 
Total cholesterol (mg/dL) 173±43 188±45 0.02 
Haemoglobin (g/dL) 12±2.0 13±1.8 0.29 
Albumin (g/dL) 4.1±0.4 4.2±0.5 0.53 
CRP (mg/L) 3.2 (1.2-10) 2.3 (1.0-5.4) 0.06 
Phosphate (mg/dL) 3.71±0.68 3.72±0.78 0.92 
eGFR (ml/min/1.73m2) 34±12 36±13 0.32 





In this study high serum IL-6 levels are associated with history of CVD and predict the 
risk for incident CV events in stage 2-5 CKD patients. Furthermore, the functional 
polymorphism -174 G/C in the promoter of IL-6 gene is associated with history of CVD 
and predicts the risk for future CV events in this population. These results are 
compatible with the hypothesis that this inflammatory cytokine is causally implicated 
in the high CV risk in CKD.  
Atherosclerosis is an inflammatory disease (1). Chronic inflammation is pervasive at 
all CKD stages, particularly in stage 5D CKD patients (13, 14). IL-6 is considered as an 
orchestrator of the inflammatory response (37) and a key player in atherosclerosis in 
humans (38). The IL-6 effect on the cardiovascular system might be mediated via 
downstream acute-phase proteins (39) or by IL-6 per sé. IL-6 stimulates endothelial 
activation, vascular smooth muscle cell proliferation (40) and leukocyte recruitment 
(41), thereby contributing to the process of atherosclerotic plaque growth (42) and 
instability (43). IL-6 mRNA is overexpressed in atheromatous arteries and IL-6 
expression co-localizes with macrophages in areas of plaque rupture (43). In the apoE-
deficient mice, systemic administration of IL-6 accelerates atherosclerosis (10). 
Elevated levels of IL-6 are predictive of future CV events in healthy men (15) and 
women (44) and are markers of poor prognosis in patients with chronic angina (45) 
and acute coronary syndrome (46).  IL-6 levels are markedly elevated in CKD, a 
phenomenon only in part explained by reduced renal clearance of this cytokine. 
Furthermore, the observation of a parallel increase in IL-6 and CRP in our study is in 
keeping with the notion that IL-6 drives the synthesis of CRP. High IL-6 has been solidly 
associated with mortality in stage 5 CKD patients maintained on chronic dialysis (16-
20). To the best of our knowledge, there is only one study which tested the 
relationship between IL-6 and CV mortality in CKD (21). This seminal study was carried 
out in a small cohort of 125 patients, was based on a quite limited number of CV events 
(n=22) and included also dialysis patients (34% of the whole cohort) (21). Our study, 
based on a large CKD cohort composed exclusively by pre-dialysis patients and 
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including a large number of CV events, confirmed pilot data by Barreto et al. (21) and 
showed that high IL-6 is coherently associated both with history of CVD as well as with 
incident CV events.  
Being observational in nature, findings in studies discussed above, including our 
analysis based on circulating IL-6, remain hypothesis generating and as such leave 
unresolved the critical question whether this cytokine is causally implicated in CV 
complications in pre-dialysis CKD patients. This question can only be resolved by a full-
fledged clinical trial.  
The Mendelian randomization approach is a useful step in the pathway to discovery 
in clinical research. Since genetic polymorphisms are distributed randomly at gamete 
formation and since genotypes precede phenotypes and do not change over time, 
comparing individuals harboring a given risk allele for the expression of a 
corresponding risk factor with those without the risk allele in question may allow 
unbiased assessment of the link between the attendant risk factor and relevant clinical 
outcomes. In this perspective, we used the functional polymorphism -174 G/C in the 
promoter of IL-6 gene as a marker to further investigate the link between IL-6 and CV 
events in CKD patients. The -174 G/C polymorphism is a common variant that 
regulates the serum concentration of IL-6 (22-28). In keeping with previous studies in 
patients with cardiovascular disease (28), coronary artery bypass grafting surgery (23, 
25), carotid atherosclerosis (24), abdominal aortic aneurysm (22) and patients in 
dialysis (26), we found that CKD patients with CC genotype had higher circulating 
levels of IL-6 and CRP than those harboring GC or GG genotypes specifically 
legitimating the use of this genetic marker as an unbiased means for assessing the 
causal nature of the link between the gene product (IL-6) of this polymorphism and 
CV complications in CKD. Interestingly, this analysis showed that this polymorphism is 
independently associated both with the history of CVD as well as with incident CV 
events. Such associations, which went along with the previously described 
relationships of serum IL-6 with the same outcomes, provide further strength to the 




Furthermore, the observation that the distribution of genotypes frequency of the -174 
G/C polymorphism in CKD patients was not in Hardy-Weinberg equilibrium and that 
the frequency of the C allele was significantly higher in CKD patients as compared with 
general population of the same geographical area, offers additional circumstantial 
evidence that IL-6 is a causal risk factor for CV events in this population (47). 
Mendelian Randomization studies support causal interpretations but do not 
constitute definitive proof for causality, which demands specific experimental 
evidence (i.e. a formal randomized clinical trial). In this respect, meta-analytic data 
from two genetic consortia exploring the effect of a polymorphism in the interleukin-
6 receptor (IL6R) on the risk of coronary artery disease, showed that the allele which 
attenuated IL-6 signaling was significantly associated with reduced risk of coronary 
heart disease (48). Notably, the relevance of this genetic association for the control of 
inflammation is showed by a meta-analysis of clinical trials testing a monoclonal 
antibody against the IL6R (Tocilizumab) in rheumatoid arthritis and documenting that 
lowering serum levels of IL-6 is an effective strategy to induce the remission of this 
chronic inflammatory disease (49).  
Some limitations should be acknowledged. First, even though our cohort study 
registered a sizeable number of cardiovascular events, the number of deaths (n=42) 
was limited, preventing adequately adjusted analyses focusing on this major outcome. 
However, the analysis of the primary outcome in this study, incident CV events, which 
was robustly based on 117 events, showed parallel links between serum IL-6 and the 
genetic marker of this cytokine with the same events. Second, although Mendelian 
randomization is a powerful approach for inferring causality in observational studies, 
there are potential limitations to its application. Genetic variants can be indicators of 
environmental exposures on condition that there is no genetic admixture, pleiotropy 
or linkage disequilibrium. However, it is reasonable to believe that in our study all 
these assumptions are fulfilled. Our population is genetically homogeneous (29) and 
the -174G/C polymorphism is a functional variant directly responsible for serum levels 
of IL-6 (22-28). Furthermore, pleiotropy seems highly unlikely because of the location 
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of -174 G/C polymorphism in the promoter region of the gene. Third, despite we 
demonstrated that our findings had high internal validity by bootstrap modeling, 
replication of the results in a second cohort is a required proof for the external 
generalizability of findings in observational studies. In this respect, our observational 
study in a large Southern European cohort is a confirmation of a small central 
European cohort (21). Furthermore, our study is the first applying a genetic marker of 
IL-6 to express the nature (causal versus not causal) of the IL6-CV events link in CKD 
patients.  
In conclusion, high serum IL-6 is associated both with history of CVD as well as with 
future CV events in CKD patients and these associations are fully confirmed by the 
application of a functional polymorphism in the IL-6 gene. Overall, this study is 
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Background: Polymorphisms in the FTO (fat-mass and obesity-associated) gene have 
been associated with body mass index, cancer, type 2 diabetes and hypertension.  
Methods: We investigated the relationship between 17 tag single nucleotide 
polymorphisms (SNPs) and all-cause mortality in 3 cohorts of dialysis patients (CREED-
1, North Apulian and CREED-2 cohorts; n=783) and in 1 cohort of stage 2-5 CKD 
patients (n= 757). 
Results: We first explored the association between the 17 tag SNPs and all-cause 
mortality in the CREED-1 cohort and found that patients with the A allele of the FTO 
rs708259 polymorphism had an elevated risk of mortality (HR: 1.52, 95% CI: 1.11-2.08; 
P=0.008). Similarly, the A allele was associated with an increased risk of death also in 
the other two dialysis cohorts (North Apulian cohort, risk: + 23%; CREED-2 cohort, risk: 
+21%). The elevated risk portended by this allele was even higher in the stage 2-5 CKD 
cohort (+97%). However, the risk of mortality associated with the A allele in the 3 
confirmatory cohorts failed to achieve formal statistical significance. In a meta-
analysis including the 4 cohorts (n=1540; total deaths, n=381), individuals with the A 
allele had a 42% excess risk of death (HR:1.42, 95% CI: 1.14-1.76, P=0.002).  
Conclusion: The A allele of the FTO rs708259 polymorphism is an independent 
predictor of all-cause mortality in patients with CKD of various severity. These data 
support our hypothesis that the FTO gene may be a relevant genetic risk factors for 













Obesity is an expanding epidemic and a public health priority worldwide. The causes 
of this epidemic are mainly environmental because obesity clusters with social 
contacts (1). Genetic background contributes substantially to the risk of obesity and it 
is estimated that genetic factors explain about a half of the variation in adipose tissue 
mass (2). Over the last two decades, a large series of genes associated with human 
obesity have been identified and for most of these genes the association with obesity 
has been replicated (3). Among these genes, the FTO (fat-mass and obesity-associated 
gene) appears of particular interest because, beyond obesity, polymorphisms in this 
gene have been associated with mortality (4), cancer (5, 6, 7), diabetes (8, 9, 10) and 
hypertension (11).  
Chronic kidney disease (CKD) is an emerging public health priority in economically 
developed and developing countries (12). The relationship between high body mass 
index (BMI) and survival in pre-dialysis (13) and dialysis (14) CKD patients seems to be 
complex.  At variance with the general population, where excess adiposity is directly 
and linearly associated with the risk of death, the same association in CKD and in 
dialysis patients is either U shaped or inverse, suggesting that a high body mass may 
be protective in this population. Whether genetic variability in the FTO gene associates 
with elevated mortality in patients with chronic kidney disease has not been 
investigated. The issue is of relevance because diabetes and hypertension, two risk 
factors which have been associated to the FTO gene, rank as major risk factors for CKD 
while dialysis patients have an exceedingly high risk of incident cancers and diabetic 
patients on dialysis have a short survival. With this background in mind, we have 
therefore designed a genetic association study testing whether the variability of the 









SUBJECTS AND METHODS 
Patients 
In the present study we included three independent cohorts of dialysis patients (the 
CREED-1 cohort, the North Apulian cohort and the CREED-2 cohort) with a total 
number of 783 patients and one cohort of stage 2-5 CKD patients (see Table 1).  
 
  Table 1. Main characteristics of dialysis patients (CREED, North Apulian and CREED 2 
cohorts) and of CKD patients 








n 265 220 298 757 
Age  
(years) 
61±15 58±16 61±15 62±11 
Male gender 
(%) 
56% 53% 63% 60% 
Diabetes  
(%) 
12% 12% 24% 35% 
BMI  
(kg/m2) 
25±4 23±4 26±5 28±5 
Systolic BP 
(mmHg)  
140±24 142±19 136±22 134±18 
Diastolic BP 
(mmHg) 










Nov 2007  
Data are expressed as mean ± SD or as percentage, as appropriate. 
 
 
CREED-1 (15) included an incident-prevalent cohort of 265 dialysis patients (age 61±15 
years; 56% Males) treated in the Urban Areas of Reggio Calabria (Calabria Region) and 
Catania (Sicily Region). These patients (all Caucasian) have been on regular dialysis 
treatment for at least 6 months, with left ventricular ejection fraction > 35% and 
without circulatory congestion, major infections (fever, infected vascular access or 
peritonitis or exit site infection) or inter-current illnesses requiring hospitalization. 
Two hundred and fourteen haemodialysis patients were being treated thrice weekly 
with standard bicarbonate dialysis (Na 138 mmol/L, HCO3 5 mmol/L, K 1.5 mmol/L, Ca 
1.25 mmol/L, Mg 0.75 mmol/L) either with Cuprophan or semi-synthetic membranes. 




hundred and five patients were habitual smokers and 109 patients were treated with 
anti-hypertensive drugs. The incident/prevalent North Apulian cohort included 220 
dialysis patients (age 58±16 years; 53% Males) (16) enrolled in the health district of 
Foggia (Puglia region). Two-hundred and ten patients were treated thrice weekly with 
standard bicarbonate dialysis (Na 138 mmol/L, HCO3 5 mmol/L, K 1.5 mmol/L, Ca 1.25 
mmol/L, Mg 0.75 mmol/L) by Cuprophan or semi-synthetic membranes and 10 
patients were on CAPD. Fifty-three patients were habitual smokers and 175 were on 
anti-hypertensive treatment. The CREED-2 cohort included 298 hemodialysis patients 
non overlapping with the CREED-1 cohort. All patients in CREED-2 were of Caucasian 
descent and were being treated in 11 dialysis units in two regions of Southern Italy 
(Calabria and Sicily) and showed the same characteristics of CREED-1 and North 
Apulian cohort patients (see Table 1). All patients had been on regular hemodialysis 
with standard bicarbonate dialysis for a median time of 42 months (inter-quartile 
range: 20-81 months) and were being treated with non-cellulosic membrane filters of 
various type. One hundred and fifty-nine patients were habitual smokers and 174 
patients were treated with anti-hypertensive drugs. The CKD cohort included 757 
consecutive patients with stage 2-5 CKD of various aetiology. These patients were 
recruited from 22 Nephrology units in Southern Italy. All patients were in stable clinical 
condition and none had intercurrent infections or acute inflammatory processes. The 
large majority of patients (97%) were being treated with anti-hypertensive drugs (51% 
were on mono/double therapy with ACE-inhibitors, calcium antagonists, angiotensin 
II receptor antagonists, diuretics, alfa and beta blockers, and clonidine and the 
remaining 49% were assuming three or more various combinations of these drugs). 
Inclusion criteria were: non acute or rapidly evolving renal diseases; age ranging from 
18 to 75 years; non-transplanted; non-pregnant, not affected by cancer or diseases in 









After the initial assessment, dialysis patients were followed up for a median time of 
44 months (range: 0.20-154 months) in the CREED-1 study, for 66 months (range: 1-
90 months) in the North Apulian cohort and for 26 months (range: 0.5-33 months) in 
the CREED-2 cohort. In the CKD cohort, patients were followed up for a median time 
of 33 months (range: 1-49 months).  In all cohorts, during the observation period, all-
cause mortality was accurately recorded and classified by trained outcome assessors.  
Haplotype structure and SNP selection 
The haploblock structure of the FTO gene for the Central European population was 
defined using Haploview (http://www.broadinstitute.org/haploview/haploview) 
(version 3.0 release R2, accessed June 2009; Whitehead Institute for Biomedical 
Research, USA). Using a minor allele frequency > 5%, a pair-wise approach and setting 
an r2 > 0.80, 16 single nucleotide polymorphisms (SNPs) (rs10163276; rs10521304; 
rs11075999; rs1125338; rs13334214; rs1078013; rs12935710; rs4784353; rs708259; 
rs7204916; rs8047395; rs860713; rs9924877; rs8044769; rs9926180; rs8050136), 
which were not in linkage disequilibrium between them, were sufficient to tag the 
haploblocks considered capturing most of the variability in the region. In addition, we 
determined the rs9939609 SNP which was in linkage disequilibrium with the 
rs8050136. This polymorphism, which maps in intron 1, has been repeatedly 
associated with fat mass in overweight and obese patients in previous large studies (8, 
17, 18, 19).  
Genotyping of the selected SNPs 
Allelic discrimination of the selected 17 SNPs was performed using TaqMan SNP 
Genotyping Assays provided by Applied Biosystems on a 7900HT Fast Real-Time PCR 
platform and its accompanying Sequence Detection System (SDS) Software version 2.4 
(Applied Biosystems, Foster City, CA, USA). Genomic DNA was extracted from 
peripheral blood leukocytes by salting-out technique (20). The reaction system 
contained 20 ng of genomic DNA, 12.5 l of 2 X TaqMan Universal PCR Master Mix No 




VIC dye-labeled TaqMan MGB probes) and H2O for a total volume of 25 l. A random 
10% of samples were independently repeated to confirm genotyping results. The 
genotype results for these samples were completely consistent. 
Laboratory measurements 
In the whole study population blood sampling was performed after an overnight fast 
always during a mid-week non-dialysis day for haemodialysis patients and at empty 
abdomen for CAPD patients. Blood was drawn and put into tubes containing EDTA, 
and plasma supernatants were stored at - 80°C until batch analyses. All analyses were 
done blinded to clinical information. Serum cholesterol, albumin and haemoglobin 
measurements were made using standard methods in the routine clinical laboratory.  
Statistical analysis 
Data were expressed as mean ± SD, median and inter-quartile range (IQR) or as 
percent frequency and comparisons between groups were made by independent T-
Test, Mann-Whitney U test or Chi Square Test, as appropriate. 
The relationship between FTO rs708259 polymorphism and all-cause mortality was 
investigated by Cox regression analysis in which the centre effect was accounted by a 
stratified analysis. As potential confounders we considered: Framingham risk factors 
(age, gender, smoking, diabetes, cholesterol and arterial pressure), anti-hypertensive 
treatment and factors peculiar to kidney failure (dialysis vintage, haemoglobin and 
albumin). A variable was considered as a confounder when it was related to both the 
exposure under investigation (the FTO rs708259 polymorphism) and the study 
outcome (all-cause mortality); was not an effect of the exposure and was not in the 
causal pathway between the exposure and outcome (21). For accounting for multiple 
testing, a Monte Carlo permutation analysis (10000 permutations) was done (22). This 
analysis provides an empirical P value (permuted P value) for the link between the FTO 
rs708259 polymorphism and all-cause mortality. The effect of the FTO rs708259 
polymorphism on the risk of mortality was investigated separately in the four study 
cohorts as well as by a meta-analysis of these cohorts. The heterogeneity of the hazard 
ratios for death associated to the FTO rs708259 polymorphism among the four cohorts 




was analysed by I2 and Q-value (23).  Data were expressed as hazard ratio (HR) and 
95% confidence interval (CI) and P value. All calculations were made by using two 
standard statistical packages (SPSS for Windows – 9.01- Chicago, Illinois, USA and 
Comprehensive Meta Analysis – Version 2.2.064, BioStat, Englewood, NJ, USA). 
 
RESULTS 
We first investigated in the CREED-1 cohort study 17 SNPs (rs10163276; rs10521304; 
rs11075999; rs1125338; rs13334214; rs1078013; rs12935710; rs4784353; rs708259; 
rs7204916; rs8047395; rs860713; rs9924877; rs8044769; rs9926180; rs8050136; 
rs9939609) capturing most of the variability of the FTO gene. All these SNPs were in 
Hardy-Weinberg Equilibrium (P ranging from 0.09 to 0.98).  Among these tag SNPs, 
the FTO rs708259 polymorphism was the only one to show an association with all-
cause mortality (P=0.008) (see below) in this cohort of dialysis patients. Then, we 
extended the analysis to other two dialysis cohorts (North Apulian and CREED-2 
cohorts) and tested the relationship of the same polymorphism with mortality in a 
fourth cohort of stage 2-5 CKD patients.  
FTO rs708259 polymorphism  
The FTO rs708259 polymorphism, either in CREED-1 study   [GG, n=89 (33.0%); AG, 
n=129 (49.0%);  AA, n=47 (18.0%), χ2=0.001, P=0.98] or in North Apulian [GG, n=43 
(19.0%); AG, n=96 (44.0%);  AA, n=81 (37.0%), χ2=2.22, P=0.14] and CREED-2 cohort 
[GG, n=94 (31%); AG, n=148 (50%); AA, n=56 (19%), χ2=0.03, P=0.87] did not deviate 
from the Hardy-Weinberg Equilibrium. Similarly, in the CKD cohort (n=759), the 
genotypic distribution of the FTO rs708259 polymorphism was in Hardy-Weinberg 
Equilibrium [GG, n=257 (34.0%); AG, n=379 (50.0%); AA, n=121 (16.0%), χ2=0.91, 
P=0.34].  
In Table 2 the main demographic and clinical characteristics of patients of the three 




Patients with AA or AG genotypes did not differ from those homozygotes for the G 
allele. The same analysis carried out separately in the three dialysis cohorts provided 
similar results (data not shown). 
 
Table 2. Main demographic, somatometric and clinical characteristics of the dialysis population 











Age (years) 60±15 60±16 0.49 
Male sex n. (%) 128 (57) 325 (58) 0.66 
Smokers n. (%) 93 (41) 224 (40) 0.82 
Diabetics n. (%) 45 (20) 96 (17) 0.35 
Dialysis vintage (months) 43 (18-99) 44 (20-99) 0.91 
*BMI (kg/m2) 24.9±4.5 25.2±5.0 0.42 
    
Systolic pressure (mmHg) 140±22 139±22 0.34 
Diastolic pressure (mmHg) 77±12 77±12 0.96 
On anti-hypertensive treatment n. (%) 127 (56) 331 (59) 0.42 
    
Cholesterol (mg/dL) 181±53 180±52 0.75 
Haemoglobin (g/L) 11.3±1.7 11±1.6 0.11 
Albumin (g/L) 3.95±0.48 3.87±0.51 0.06 
Data are expressed as mean± SD. median and inter-quartile range or as percent 
frequency. as appropriate. Comparisons between groups were made by independent 
T-test, Mann Witney U test or Chi-Square Test, as appropriate.  
Symbol: 




FTO rs708259 polymorphism and survival in dialysis patients 
During the follow-up period (median: 44 months, range: 0.2-154 months) of the whole 
study population of dialysis patients (n=783), 339 patients died, 172 of them (51%) of 
cardiovascular causes. On univariate Cox regression analysis, the excess risk of death 
was 41% higher (hazard ratio: 1.41, 95% CI: 1.10-1.81, P=0.008; permuted P 
value=0.006) in patients with AA or AG genotypes than in those with GG genotype 
(Figure 1), and the excess risk in the three combined cohorts did not differ from that 
observed in the three cohorts considered separately (CREED-1 cohort, excess risk: + 




52%; North Apulian cohort, excess risk: + 23%; CREED-2 cohort, excess risk: +21%) 
(Figure 2). 
Adjustment for albumin (which was the only variable that tended to be different 
among genotypes) (see Table 2) had no material effect on the strength of the 
association between the FTO rs708259 polymorphism and the risk of mortality 
(HR:1.41, 95% CI: 1.10-1.82, P=0.007, permuted P value=0.005).   
 
Figure 1. Kaplan-Meier survival curves of all-cause mortality in the whole dialysis population 
(CREED-1, North Apulian and CREED-2 cohorts; n=783) according to the genotypes of the FTO 






FTO rs708259 polymorphism and survival in stage 2-5 CKD patients 
During the follow-up period (33 months, range 1-49 months), 42 CKD patients died, 
31 (74%) of them of CV causes. On univariate Cox regression analysis, CKD patients 
having AA or AG genotypes of the FTO rs708259 polymorphism had an excess risk of 




excess risk did not differ (P=0.32) from that observed in dialysis patients. However, 
probably due to the small number of death cases in this cohort of pre-dialysis patients, 
such a risk excess failed to achieve formal statistical significance (HR:1.97, 95%CI: 0.94-
4.11; P=0.07) in this cohort (Figure 2).  
 
Figure 2. Hazard ratios (and 95% confidence intervals) of the FTO rs708259 polymorphism for 
all-cause mortality in the study cohorts. At the bottom of the figure, a pooled analysis of all 





Meta-analysis of the four study cohorts 
There was no effect heterogeneity (P=0.74) of FTO rs708259 polymorphism on the risk 
of mortality in patients with kidney failure and in those with stages 2-5 CKD and for 
this reason fixed- and random-effects models provided identical results. In a meta-
analysis of the four cohorts (total number of patients, n=1540; total deaths, n=381), 
AA or AG individuals had a 42% excess risk of mortality as compared to those 
homozygotes for the G allele (HR: 1.42, 95% CI: 1.14-1.76, P=0.002) (Figure 2) further 




confirming that the A allele of the FTO rs708259 polymorphism associates with 
reduced survival in CKD patients.  
 
DISCUSSION 
This study shows an association between the A allele of the FTO rs708259 
polymorphism and all-cause mortality in pre-dialysis and dialysis patients. 
FTO gene and obesity 
The fat-mass and obesity-associated (FTO) gene has been repeatedly associated with 
various obesity traits (8, 17, 18, 19, 24), insulin resistance and type 2 diabetes (8, 9, 
10). This gene codes for an enzyme that oxidatively demethylates single-stranded DNA 
(25) and, by this mechanism, it may modulate relevant epigenetic modifications of 
other fundamental genes regulating various biological processes. A common sequence 
variant in the first intron of this gene, the rs9939609, predisposes to type 2 diabetes 
through an effect on body mass index (BMI) (8) and an association between this 
polymorphism and the BMI has been replicated in 13 external cohorts including 
38,759 European subjects (8). Furthermore, other FTO polymorphisms have been 
associated with severe obesity in individuals of French descent (18).  
FTO gene and renal disease 
Although studies performed so far have primarily focused on the association between 
the FTO gene and obesity, variants in this gene associate also with other major clinical 
conditions, including cancer (5, 6, 7), hypertension (11), Alzheimer’s disease (26) and 
kidney failure (27). The FTO is one of the largest genes (more than 4 Mb) which have 
been implicated in human health.  To study the association between genetic variants 
in FTO gene, we selected 17 tag SNPs that reflected the haploblock structure of the 
gene. Of these SNPs, none of those localized in intron 1 was associated with mortality. 
However, in the first cohort enrolled in this study (CREED-1 cohort), we identified a 
new polymorphism, the rs708259 on intron 8 of the FTO gene, which was strongly 
associated with death in dialysis patients. When we extended the analysis to two 




patients comparable for the main demographic and clinical characteristics to the first 
cohort, we observed again an excess risk of death (+23% and + 21%, respectively) in 
A-allele carriers. Importantly, such an association was also confirmed in a third 
independent cohort of stage 2-5 CKD patients. Although the associations between the 
rs708259 polymorphism and mortality did not attain formal statistical significance in 
the three confirmatory cohorts, a meta-analysis of the 4 cohorts showed that 
individuals harbouring the risk allele A of the FTO rs708259 polymorphism have a 
highly significant (p=0.002) 42% excess risk of death as compared to individuals 
without such an allele.  
To the best our knowledge, this is the first study investigating the role of the FTO gene 
on mortality in pre-dialysis and dialysis patients. The FTO rs708259 polymorphism in 
intron 8 is not in linkage disequilibrium with any of the SNPs in the intron 1 of the 
gene. While the association between the FTO rs708259 polymorphism and mortality 
in pre-dialysis and dialysis patients in our data is statistically robust, the functional 
significance of this SNP is unknown. Because the FTO rs708259 polymorphism is 
unrelated to BMI and diabetes, it seems unlikely that the FTO gene affects survival 
through its impact on mechanisms regulating energy balance or glucose metabolism 
in this population. We speculate that this polymorphism may exert functional effects 
by modifying the bioavailability of the transcript and/or the protein product of FTO. 
Alternatively, this polymorphism may enhance the risk of mortality via DNA 
methylation. Functional studies in appropriate models are needed to mechanistically 
interpret the association between the FTO rs708259 polymorphism and mortality in 
the CKD population.  
In conclusion, our findings generate the hypothesis that CKD patients of various 
severity with the A allele of the FTO SNP rs708259 polymorphism may have a higher 
death risk than those without such an allele. Functional studies will define the 
mechanism(s) whereby this polymorphism impacts upon survival in this population.  
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Background: Resistin is a major adipose tissue cytokine implicated in insulin 
resistance, inflammation and vascular damage. This cytokine is raised in patients with 
End-Stage Kidney Disease (ESKD) but the relationship between resistin and major 
clinical outcomes has not been investigated in this population.  
Methods: We studied the mutual relationship between resistin and the two major 
adipokines (adiponectin and leptin) and the interaction between resistin and 
adiponectin (ADPN) and all-cause and cardiovascular (CV) mortality in a cohort of 231 
hemodialysis patients followed up for 57±44 months. 
Results: Plasma Resistin was substantially raised in ESKD patients as compared to 
healthy subjects (P<0.001). On univariate analysis, resistin was related inversely to 
ADPN (r=-0.14, P=0.04) and directly to C-Reactive Protein (r=0.15, P=0.03) but was 
largely independent of leptin (r=0.08, P=0.24) and HOMA-IR index (r=-0.04, P=0.51). 
During the follow-up, 165 patients died (96 for CV causes). On both univariate (all-
cause mortality: P=0.004; CV mortality P<0.001) and multivariate (all-cause mortality: 
P=0.01; CV mortality P<0.001) Cox regression analyses the effect of resistin on study 
outcomes was closely dependent on ADPN levels. There was a consistent excess risk 
for all-cause (P=0.002) and CV mortality (P=0.003) by plasma resistin (20 ng/mL) in 
patients in the first ADPN tertile but no risk excess for these outcomes was apparent 
in patients in the third tertile.  
Conclusion: This study indicates that resistin predicts death and fatal CV events 
depending on plasma ADPN levels. These findings underscore the importance of the 










Over the past decade numerous clinical studies focusing on the relationship between 
two main adipokines, adiponectin (ADPN) and leptin, and major clinical events in end-
stage kidney disease (ESKD) patients have been published (1-5). Resistin is a cysteine 
rich molecule of the “found in inflammatory zones” (FIZZ) proteins, which is 
synthesized in the adipose tissue (6, 7) and in macrophages (8, 9). High levels of this 
peptide go along with inflammation and insulin resistance both in experimental 
models (6, 10, 11) and in vivo in man (12-14). Interest on resistin in ESKD has been 
much limited and until now no study tested the relationship between this cytokine 
and major clinical outcomes, including all-cause and cardiovascular (CV) death, in this 
population. The issue is of relevance because high resistin associated with mortality 
and incident heart failure in patients with coronary heart disease (15) or with acute 
myocardial infarction (16). Furthermore, a most risky arrhythmia like atrial fibrillation 
was predicted by resistin levels in the Framingham Heart study population (17). 
Adipose tissue cytokines have mutual inter-relationships and interact with abdominal 
obesity in determining death and CV events (4).  Furthermore, ADPN is a modifier of 
the relationship between leptin and fat mass in young individuals (18) and modulates 
the risk for type-2 diabetes by leptin in the general population (19).  
With this background in mind, we identified the functional correlates of circulating 
resistin in ESKD patients and studied the relationship between resistin, death and 
incident CV events as well as the interaction between resistin and the adipokine which 
emerged as its strongest functional correlate, adiponectin, and all-cause and CV 
mortality.  
 
SUBJECTS AND METHODS 
Protocol 
The protocol was in conformity to the ethical guidelines of our Institutions and 
informed consent was obtained from each participant. All blood samples for 




laboratory tests were taken during a mid-week non-dialysis day, between 8 A.M. and 
1 P.M. 
Patients and controls 
We studied an incident-prevalent cohort of 231 hemodialysis patients (127 M and 104 
F) who had been on regular dialysis treatment (RDT) for at least 6 months. The 
enrolment criteria in this cohort were no history of congestive heart failure [defined 
as  dyspnea in addition to two of the following conditions - raised jugular pressure, 
bibasilar crackles, pulmonary venous hypertension or interstitial oedema on chest X 
ray, requiring hospitalization or extra ultra-ultrafiltration],  left ventricular ejection 
fraction >35% and no inter-current or terminal illnesses.  Patients were treated thrice 
weekly with standard bicarbonate dialysis (Na 138 mMol/L, HCO3 35 mMol/L, K 1.5 
mMol/L, Ca 1.25 mMol/L, Mg 0.75 mMol/L) either with cuprophan or semi-synthetic 
membranes (dialysis filters surface area: 1.1-1.7 m2).    
For comparison, we assessed resistin plasma concentration in 41 healthy volunteers. 
Laboratory measurements  
Blood sampling was performed after an overnight fast between 8.00 a.m. and 10.00 
a.m. always during a mid-week non-dialysis. After 20-30 min of quiet resting in semi-
recumbent position samples were taken into chilled EDTA vacutainers, placed 
immediately on ice, centrifuged within 30 min at -4°C and the plasma stored at -80°C 
before assay. Serum lipids, albumin, glucose, phosphate, and haemoglobin 
measurements were made using standard methods in the routine clinical laboratory. 
Plasma concentration of C-Reactive Protein (CRP), leptin and adiponectin were 
measured according to methods described elsewhere (1). Plasma levels of IL-6 and 
TNF  were measured by using commercially available kits (R&D Systems, 
Minneapolis, Minnesota). The intra-assay coefficient of variation for these molecules 
ranged from 2.6% to 4.7% and interassay coefficient of variation from 4.5 to 5.8%. 
Plasma resistin was measured by ELISA (Bio Vendor Laboratory Medicine Inc., Brno 
Czech Republic). The intra-assay coefficient of variation was 4.3% and the inter-assay 




was 10.8 + 6.2 ng/mL with a normal range spanning from 1.2 ng/mL to 29.9 ng/mL. 
Serum insulin levels were measured by using a commercially available RIA kit (Sorin 
Saluggia, Vercelli, Italy). Insulin sensitivity was estimated by using the homeostatic 
model assessment (HOMA-IR) index [i.e., plasma glucose level × (plasma insulin 
level/22.5)]. 
Follow-up study 
After the initial assessment, patients were monitored for 57 ± 44 months (range: 0.2 
to 155 months). During the follow-up period, fatal cardiovascular events (ECG 
documented myocardial infarctions, heart failure, ECG documented arrhythmia, 
strokes, peripheral vascular disease, or major arterial or venous thrombotic episodes) 
and death for other causes were accurately recorded. Each death was reviewed and 
assigned an underlying cause by a panel of five physicians. As part of the review 
process, all available medical information regarding each death was collected. This 
information always included study and hospitalization records. In the case of an out-
of-hospital death, family members were interviewed by telephone, for better 
assessment of the circumstances surrounding the death.  
Statistical analysis 
Data were expressed as mean ± standard deviation (SD), median and inter-quartile 
range (IQR) or as percent frequency, as appropriate.  Comparisons among groups were 
made by P for linear trend. The association between two continuous variables was 
assessed by the Pearson product moment correlation coefficients and between binary 
and continuous variables by the point-biserial correlation coefficient. Variables having 
a positively skewed distribution were log transformed (lg10) before the correlation 
study. The effect modification of ADPN (i.e. the interaction analysis) (20) on the 
relationship between resistin and all-cause and cardiovascular mortality was 
investigated by univariate and multivariate Cox regression analyses. In multivariate 
models we included resistin, ADPN and their interaction term [resistin (20 ng/mL 
increase) * ADPN (tertiles)] as well as traditional risk factors (age, gender, smoking, 
systolic pressure, cholesterol, diabetes, previous cardiovascular events, BMI), factors 




peculiar to ESRD (haemoglobin, albumin, phosphate, dialysis vintage) and CRP. By this 
strategy we built up models of adequate statistical power for all-cause mortality (at 
least 1 variable every 11 deaths). In these analyses ADPN was modelled in terms of 
tertiles because this functional form was the one that optimized data fitting (21).To 
account for over-fitting for cardiovascular mortality, a shrinkage analysis was 
performed (22). The proportionality assumption was tested by analysing the 
Schoenfeld residuals and no violation was found. The hazard ratios of a fixed increase 
in Resistin (20 ng/mL) across ADPN tertiles were calculated by the linear combination 
method. Data were expressed as hazard ratios, 95% CIs and P values. All calculations 
were done by standard statistical packages (SPSS for Windows Version 9.0.1, 11 Mar-




The study population included 231 haemodialysis patients (age: 60±15 years; Males: 
55%) on regular dialysis treatment for a median time of 41 months (inter-quartile 21-
106 months) (see Table 1).  
One hundred and fifteen patients (50%) had previous CV events, 35 were diabetic 
(15%) and 86 (37%) were habitual smokers (22±16 cigarettes/day). Eighty-four 
patients (36%) were on anti-hypertensive treatment (59 on mono-therapy with ACE 
inhibitors, AT-1 antagonists, Calcium channel blockers, alpha and beta-blockers and 
25 on double or triple therapy with various combinations of these drugs). One 
hundred and twenty six patients (55%) were treated with erythropoietin. Average 
urea Kt/V was 1.22±0.27. 
Correlates of plasma Resistin  
Plasma resistin in ESKD patients had a normal distribution with an average value of 
117.2±23.3 ng/mL which was about 11 times higher than the average normal value 
(10.8+6.2 ng/mL) and exceeded the upper limit (29.9 ng/mL) of the normal range in 









Age (years) 60±15 
Male sex n. (%) 127 (55) 
BMI (kg/m2) 24.5±4.4 
Diabetics n. (%) 35 (15.2) 
Smokers n. (%) 86 (37.2) 
Patients with CV comorbidities n. (%) 115 (50%) 
Dialysis vintage  41 (21-106) 
Kt/V 1.22±0.27 
On EPO treatment n. (%) 126 (55%) 
On-anti-hypertensive treatment n. (%) 84 (36%) 
Systolic BP (mmHg) 139±25 
Diastolic BP (mmHg) 76±13 
  
Total cholesterol (mg/dL) 208.7±57.8 
Glucose (mmol/L) 5.6±3.2 
Insulin (µU/mL) 19.8(13.7-29.7) 
HOMA-IR (µU/mL*mmol/L) 4.0(2.7-6.8) 
Haemoglobin (g/dL) 10.7±1.9 
Albumin (g/dL) 4.2±0.5 
Phosfate (mg/dL) 4.5±1.1 
CRP (mg/L) 7.4 (3.4-16.3) 
IL-6 (pg/mL) 5.0 (2.8-9.2) 
TNF-(pg/mL) 5.6 (1.8-1.5) 
Resistin (ng/mL) 117.2±23.3 
Adiponectin ( g/mL) 15.0±7.7 
Leptin (ng/mL) 10.0 (4.8-30.7) 
Data are expressed as mean± SD, median and inter-quartile range or as percent 























Figure 1. Distribution of plasma resistin in the study population. All ESKD patients exceeded the 




Plasma resistin was weakly related to plasma ADPN (r=-0.14, P=0.04) (Figure 2a) but 
was largely unrelated with leptin (r=0.08, P=0.24) (Figure 2b) and with insulin (r=0.01, 
P=0.99) and HOMA-IR index (r=-0.04, P=0.51). Furthermore, resistin was weakly 
related with dialysis vintage (r=0.21, P=0.002), CRP (r= 0.15, P=0.03) and with age (r= 
-0.17, P=0.01). 
 






During the follow-up period, 165 patients died, 96 of them for CV causes. Resistin 
failed to significantly predict all-cause and CV mortality (P=NS). On univariate Cox 
regression analysis, patients in the lowest ADPN tertile had higher all-cause mortality 
rate (19 deaths/100 persons year) when compared to those in the second (11 
deaths/100 persons year) and third ADPN tertile (17 deaths/100 persons year) (P for 
trend=0.02). The same analysis carried out for CV mortality provided similar results 
(ADPN, I tertile: 13 CV deaths/100 persons year; II tertile: 6 CV deaths/100 persons 
year; III tertile: 8 CV deaths/100 persons year)(P for trend =0.02). Formal interaction 
analysis showed that ADPN is a strong modifier of the relationship between resistin 
and study outcomes both on univariate (all-cause mortality: P for effect 
modification=0.004; CV mortality: P for effect modification<0.001) or on multivariate 
Cox regression analyses (Table 2 and Figure 3).  
Indeed, the risk excess for all cause and CV mortality portended by a fixed increase in 
resistin (20 ng/mL) was apparent and highly significant (all-cause mortality: P for effect 
modification=0.01; CV mortality: P for effect modification<0.001) in patients with low 
ADPN (first ADPN tertile all-cause death, HR: 1.32, 95% CI: 1.11-1.58; CV death, HR: 
1.42, 95% CI: 1.12-1.79), slight and not significant in those in the second tertile (all-
cause death, HR: 1.10, 95% CI: 0.95-1.27; CV death, HR: 1.04, 95% CI: 0.86-1.26) and 
absent (all-cause death, HR: 0.91, 95% CI: 0.73-1.14; CV death, HR: 0.77, 95% CI: 0.57-
1.02) in patients in the third ADPN tertile (Figure 3). 
The effect modification by ADPN on the resistin-CV mortality link remained significant 
(P=0.006) also after Shrinkage correction accounting for over-fitting. No interaction was 
found between ADPN and resistin with CRP, IL-6 and TNF-α (all P=NS). Forcing plasma 
leptin, insulin and HOMA-IR into the multivariate models of all-cause and CV death did 
not affect the strength of the relationship between the resistin-ADPN interaction term 








Table 2 Multiple Cox regression model of the adiponectin- resistin interaction for all-cause and 
cardiovascular mortality 
 
Variables (units of increase) 
 All-cause mortality 
 
         CV mortality 
Hazard ratio (95% CI) P value 
 Hazard ratio (95% 
CI) 
   P value 
Resistin (20 ng/mL) 
See Fig.3 




(P for effect 
modification<0.001)* 
 
ADPN tertiles, g/mL (Ist ≤11.1, IInd 
11.1-16.3, IIIrd>16.3) 
 
ADPN x Resistin  
BMI (1 kg/m2) 
1.02 (0.98 to 1.06) 0.37 
 
1.05 (0.99 to 1.10) 0.09 
Framingham risk factors   
 
  
Age (1 yr) 1.04 (1.03 to 1.06) 
<0.001  
1.05 (1.02 to 1.07) <0.001 
Male gender 1.85 (1.20 to 2.86) 
0.005  
1.79 (1.01 to 3.18) 0.05 
Smoking 1.16 (0.78 to 1.74) 0.72 
 
1.47 (0.88 to 2.43) 0.14 
Systolic pressure (1 mmHg) 0.99 (0.99 to 1.01) 0.48 
 
1.00 (0.99 to 1.01) 0.40 
Cholesterol (1 mg/dL) 1.01 (0.99 to 1.01) 0.37 
 
1.00 (1.00 to 1.01) 0.10 
Diabetes  2.34 (1.50 to 3.67) <0.001 
 
2.29 (1.30 to 4.03) 0.004 
Previous cardiovascular events 1.80 (1.27 to 2.56) 0.001 
 
2.20 (1.37 to 3.52) 0.001 
Factors peculiar to ESRD   
 
  
Haemoglobin (1 g/dL) 1.09 (0.99 to1.20) 0.09 
 
1.19 (1.04-1.36) 0.01 
Albumin  (1 g/dL) 0.72 (0.50 to 1.04) 0.08 
 
0.82 (0.5 to 1.36) 0.45 
Phosphate (1 mg/dL) 1.04 (0.92 to 1.19) 0.50 
 
1.05 (0.89 to 1.25) 0.57 
Dialysis vintage (1 month) 1.00 (0.99 to 1.01) 0.80 
 
1.00 (1.00 to 1.01) 0.58 
Emerging risk factors   
 
  
CRP (1 mg/L) 1.01(1.00 to 1.01) 0.03 
 
1.00 (0.99 to 1.01) 0.75 
  Data are expressed as hazard ratio, 95% CI and P value. 










Figure 3. Effect modification of plasma adiponectin (ADPN) (expressed in tertiles) on the link 
resistin-mortality. The risk excess for all-cause and CV mortality portended by a fixed increase 
in resistin (20 ng/mL) is highly significant in patients in the first ADPN tertile, slight and not 
significant in those in the second tertile and absent in patients in the third tertile. Data are 






Resistin is markedly raised in ESKD patients, is weakly related with inflammation, does 
not associate with insulin sensitivity and correlates inversely with ADPN. Furthermore, 
the association of resistin with all-cause death and fatal CV events is strongly 
dependent (effect modification) on concurrent ADPN levels, being apparent and highly 
significant only in patients with low ADPN. This finding implies that high ADPN acts as 
a factor protecting from the noxious health effects of increased resistin in this 
population.  
Adipocytes are considered as the sole source of resistin in mice (6, 7) where this 
adipokine is implicated in insulin resistance and hyperglicemia (6, 7, 10). In man this 
molecule is expressed primarily in macrophages and is involved in inflammatory 
processes (8, 13). It is interesting to note that plasma resistin correlates more closely 
with inflammation than with insulin resistance in overweight subjects as well as in 




patients with chronic kidney disease (23-25). Plasma resistin is markedly elevated in 
ESKD (26, 27) and it is still debated if this phenomenon is a mere consequence of 
accumulation secondary to reduced renal clearance and if it may also reflect chronic 
inflammation (27). We found that, resistin in ESKD patients was not only higher than 
in normal subjects but also significantly related with serum level of CRP while it did 
not correlate with insulin resistance as assessed by circulating levels of insulin and 
HOMA-IR index, a finding confirming observations in pre-dialysis CKD patients (26). 
Resistin exerts a pro-inflammatory effect on vascular endothelial cells via up-
regulation of endothelin-1 (ET-1), vascular cell adhesion molecule-1 (VCAM-1) and 
monocyte chemoattractant protein-1 (MCP-1) (28, 29), which are all critical mediators 
of the early steps of the atherosclerosis process (30). In diabetic and non-diabetic 
patients, plasma resistin levels associate with inflammatory markers as well as with 
coronary artery calcification (14). Of note, recent evidence points to resistin as a 
cogent predictor of incident coronary heart disease (CHD) and congestive heart failure 
(CHF) in the general population (31). High resistin is also strongly and independently 
associated with major CV events and all-cause mortality in type 2 diabetes patients 
(32). However, in patients with stable CHD, the association between resistin and 
mortality in an unadjusted analysis was largely due to confounding by traditional CV 
risk factors and CKD (15).  
Risk for all-cause and CV death associated with resistin in ESKD 
The association between resistin and major clinical outcomes like mortality and CV 
events was tested in two studies in patients with coronary heart disease (15) or fatal 
myocardial infarction (16) and in both studies high resistin signalled a high death risk 
or an increased incidence of heart failure. ESKD patients are a population with 
exceedingly high risk for death and CV events (33). Causal risk factors for such a high 
risk are still not well defined and therefore testing the hypothesis that resistin is 
implicated in this high risk is a relevant question with etiologic and prognostic 
implications. In this regard, our study is the very first investigating the relationship 




predicted death and fatal CV outcomes in individuals with low ADPN but not in those 
with normal or high ADPN. This association was statistically strong and quantitatively 
of potential clinical relevance. The effect modification by ADPN on the relationship 
between resistin and mortality and fatal CV events has biological plausibility because 
ADPN and resistin have opposite effects on endothelial function and on the 
atherosclerotic process, resistin being a noxious factor for the CV system and ADPN a 
protective one. Of note, in our study the effect modification by ADPN on the resistin-
mortality and resistin-CV mortality relationships was fully independent of potential 
confounders, including traditional CV risk factors as well as risk factors peculiar to 
ESKD, including haemoglobin, albumin and CRP.  
In conclusion, we found that in ESKD, ADPN is a modifier of the link between resistin 
and mortality. Indeed, the risk for all-cause and CV mortality portended by a fixed 
increase in plasma resistin is evident in patients with low levels of ADPN but absent in 
those with high levels of this adipokine. These data underscore the importance of 
interaction analysis among adipokines to fully capture the relevance of their 
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Oxidized LDL, Gamma-glutamyltransferase (GGT) and 
adverse outcomes in older adults 
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Background/Objectives: Gamma-glutamyltransferase (GGT) is a biomarker of liver 
disease and oxidative stress which was associated with all-cause and cardiovascular 
(CV) mortality in the general population and in patients with high risk conditions. This 
study aims at assessing whether oxLDL modifies the relationship between GGT, all-
cause and CV mortality in elderly individuals from the general population. 
Design: Observational longitudinal study. 
Setting: Population-based cohort of older individuals (>65 years) free of liver disease.  
Participants: One thousand and thirty-eight individuals from the Invecchiare in Chianti 
(InCHIANTI) study.  
Measurements: serum GGT level, oxidized low-density lipoprotein (oxLDL), CV 
comorbidities, all-cause and CV mortality. 
Results: The median age of the study population (n=1038) was 74 years (inter-quartile 
range: 69-79), 152 individuals (15%) had past CV events. During a median follow-up of 
9 years, 401 individuals died, 168 of them (42%) for CV causes. In adjusted analyses, 
GGT predicted all-cause mortality (HR for 20U/L increase in serum GGT:1.11, 95% 
CI:1.02-1.21, P=0.02) and CV mortality (HR:1.17, 95%CI:1.03-1.33; P=0.02). 
Furthermore, in an analysis for interaction circulating oxLDL amplified the effect of 
GGT on all-cause mortality (P=0.003). 
Conclusions: Circulating oxLDL amplifies the effect of GGT on mortality in the elderly. 
The mechanism for this association remains unknown and requires further research, 
including studying the potential role of GGT in oxidative stress. These results are 
consistent with the hypothesis of a causal role of GGT in the CV morbidity and 
mortality in older individuals and indicate that oxLDL plays a crucial role in the 









Aging is characterized by a progressive decline of anatomic integrity and function 
across multiple tissues and organs. A number of mechanisms have been proposed to 
drive the aging process, including accumulation of damaged macromolecules due to 
oxidative stress (1). 
Gamma-glutamyltransferase (GGT),  a multifaceted  biomarker impinging upon  
oxidative  stress  (2,3), emerged as a risk factor for all-cause and cardiovascular (CV) 
mortality in population-based studies independent of liver disease and alcohol intake 
(4, 5). GGT has been detected within atherosclerotic plaques of cerebral and coronary 
arteries where it co-localizes with oxidized low-density lipoprotein (oxLDL) (6, 7). In 
theory, such a co-localization may be key to the interpretation of oxidative stress 
damage in the arterial system.  
In the sole study in an elderly cohort testing the relationship between GGT and 
mortality and CV events, this biomarker was a direct predictor of adverse clinical 
outcomes (8) which  contrasts with age-stratified analyses in community-based 
studies where GGT predicted mortality in the young and middle age strata but not in 
the elderly (9-12). Herein, we tested the relationship between GGT and all-cause and 
CV mortality in a population-based cohort of elderly individuals (n=1038) from the 
Invecchiare in Chianti study, which enrolled a random sample of people older than 65 
years living in the Chianti area in Tuscany and followed up them for a median time of 
9 years. In light of the pathophysiological relationship between GGT and oxLDL alluded 
to before (6), a pre-specified goal of the present study was testing whether oxLDL 




The elderly InCHIANTI (13) population included 1155 participants aged between 65 
and 102 years randomly selected from residents in the Chianti geographic area. The 
baseline data collection started in September 1998 and lasted until March 2000; 




thereafter, participants were fully re-evaluated every 3 years and the fourth follow-
up is still ongoing.  
The present study was performed on 1038 participants out of the 1155 original cohort 
because we excluded individuals with missing serum GGT (n=112), documented liver 
disease (n=4) or because of extremely high serum level of GGT (n=1) identified as a 
statistically significant outlier (GGT=565 U/L) by Grubbs’ test (P<0.001).   
Alcohol consumption was assessed by self-reported daily intake of wine, beer and 
spirits. The content of ethyl alcohol was calculated as follows: 5 g ethyl alcohol in 100 
mL of beer, 13 g in 100 mL of wine and 50 g in 100 ml of spirits. In agreement with 
WHO Guidelines, 40 g/day ethyl alcohol for males and 20 g/day for females were taken 
as a cut-off for identifying heavy drinkers. 
Follow-up and incident study outcomes  
The primary outcomes were all-cause and CV mortality. After the enrolment, 
individuals were monitored for a median of 9 years (ranging from 0.15-10.5 years). CV 
deaths were classified following ICD9 diagnosis codes from 410 to 438. 
Laboratory measurements 
Serum GGT was measured through an enzymatic colorimetric assay using a Roche 
analyzer (Roche Diagnostics, GmbH, Mannheim, Germany). The minimum detectable 
threshold was 3 U/L and the measure range was 3-1200 U/L. The intra-assay 
coefficient of variation (CV) was 1.5% and the inter-assay CV was 1.4%. The normal 
values considered for GGT were: 10-50 U/L in men and 10-38 U/L in women.  Oxidized 
LDL was measured using an enzyme-linked immunoassay (ELISA) kit (Mercodia AB, 
Uppsale, Sweden). The intra-assay and the inter-assay CV was 6% and 5%, 
respectively.  High sensitivity C-reactive protein (CRP) was measured by a colorimetric 
competitive immunoassay that uses purified protein and polyclonal anti-CRP 
antibodies. The minimum detectable threshold was 0.03 mg/L and the inter-assay CV 
was 5%. Homocysteine were measured by fluorimetric polarized immunoassay 
method (IMX, Abbott Laboratories). The minimum detectable threshold was 0.5 





Cross-sectional data were analyzed by univariate and multiple linear, logistic and Cox 
regression analyses. Multiple models included GGT as well as traditional risk factors 
(age, gender, smoking, diabetes, LDL cholesterol and blood pressure), factors peculiar 
to liver disease (transaminases, alkaline phosphatase, alcohol consumption), BMI, 
hemoglobin, oxidized LDL, C-reactive protein (CRP), homocysteine and creatinine 
clearance. To account for over-fitting (i.e. when the number of covariates overcame 1 
variable every 10 study outcomes) a shrinkage correction was  applied to  Cox and 
logistic regression models (14). A backward elimination strategy was applied to logistic 
regression analysis. Interaction analysis was performed by the standard linear 
combination method. The proportionality assumption was tested by analyzing the 
Schoenfeld residuals and no violation was found. The functional form of key-
covariates (including interaction term) was investigated by the analysis of Martingale 
residuals and the use of both risk factor (GGT) and effect modifier (oxLDL) as 
continuous variables resulted to be the best functional form for capturing the risk of 
all-cause and CV mortality explained by this biomarker. To assess whether early deaths 
could affect the study results a sensitivity analysis excluding patients who died within 
the first year from the enrolment was carried out. Furthermore, to minimize the 
potential distortion of heavy drinking (> 40 g/day ethyl alcohol for males and 20 g/day 
for females) a sensitivity analysis excluding heavy drinkers was performed. Data were 
expressed as odds ratio (OR), hazard ratios (HR), 95% confidence intervals (CI) and P 
values, as appropriate. All analyses were performed by standard statistical packages 
(SPSS for Windows Version 9.0.1, 11 Mar-1999, Chicago, Illinois, USA; STATA/SE 9.0 
StataCorp LP, TX, USA).  
 
RESULTS 
The main demographic and clinical characteristics of the study population are 
summarized in Table 1. The study cohort included 1038 subjects (43% males) with a 
median age of 74 years (inter-quartile range: 69-79). Biochemical parameters, 




including liver enzymes, were in the normal range and the mean value and SD of oxLDL 
was 42±13 U/L. 
 
 
 Table 1. Main Demographic, Somatometric and Clinical Characteristics of the Study Population 
 
 N=1038 
Age (years) 74 (69-79) 
Males (%) 454 (43) 
Diabetes (%) 114 (11) 
Smoking (%) 141 (14) 
CV comorbidities (%) 152 (15) 
Alcohol consumption (g/day)  8.8 (0-29.9) 
BMI (kg/m2) 27 (15-30) 
Systolic BP (mmHg) 150±20 
Diastolic BP (mmHg) 84±9 
Lipid-lowering agents 45 (4) 
Glucose (mg/dL) 89 (81-100) 
LDL cholesterol (mg/dL) 136±34 
Haemoglobin (g/dL) 13.7 ±1.4 
C reactive protein (g/mL) 2.8 (1.3-5.9) 
Alkaline phosphatase (U/L) 203 (168-246) 
 
Homocysteine (µmol/L) 14.5 (12.2-17.8) 
GGT (U/L) 19 (14-28) 
AST (U/L) 20 (17-23) 
ALT (U/L) 17 (13-22) 
oxLDL (U/L) 42±13 
 
Creatinine clearance (ml/min/1.73m2) 65±19  
Past CV events were defined as the presence of at least one of the 
following documented comorbidities at enrolment: myocardial 
infarction, angina, peripheral vascular disease, stroke or coronary 
surgery/angioplasty. 
Data are expressed as mean± SD, median and inter-quartile range or as 
percent frequency as appropriate. Abbreviations: BMI=body mass index; 
BP=blood pressure; LDL=low-density lipoproteins; GGT= gamma-
glutamyltransferase; AST= aspartate aminotransferase; ALT=alanine 








Clinical and functional correlates of GGT 
Serum levels of GGT had a left skewed distribution with a median value of 19 U/L 
(inter-quartile range: 14 to 28 U/L) (Figure 1).  
 
 





In a multiple linear regression model, including all univariate correlates of GGT, the 
independent correlates of this biomarker were ALT, male gender, C reactive protein, 
alcohol consumption, alkaline phosphatase, hemoglobin, CV comorbidities, oxLDL and 
homocysteine whereas AST, creatinine clearance, BMI, smoking, age, systolic BP, LDL 
cholesterol, diabetes and lipid lowering agents were not (P ranging from 0.28 to 0.99) 








Supplementary Table I. Correlation matrix of the functional correlates of GGT and independent 
correlates of GGT 
 
Data are Pearson product moment correlation coefficients and P values. In the multiple 
linear regression model we introduced systolic BP (as an indicator of BP burden) instead of 
diastolic BP and diabetes instead of serum glucose. However, also forcing diastolic BP 





GGT and past CV events 
At baseline, 207 past CV events occurred in 152 individuals. In detail, myocardial 
infarction in 25 cases, coronary surgery/angioplasty in 16 cases, stroke in 36 cases, 
angina in 34 cases, peripheral vascular disease in 96 cases. In logistic regression 
analysis, GGT adjusted for age and sex was associated (P=0.03) with past CV events 
(OR:1.14, 95%CI:1.01-1.27). In a parsimonious backward logistic regression model 
adjusting for age, sex, CRP, alcohol consumption, ALT and diabetes the OR of a 20 U/L 
increase in GGT for the risk of past CV events was 1.23 (95%CI:1.06-1.43; P=0.01). 
Furthermore, the GGT-CV link was confirmed in a multiple logistic regression model 
[(OR:1.24, 95%CI:1.07-1.44; P=0.005); (shrinkage corrected OR:1.19, 95%CI:1.02-1.39; 
 
Correlation matrix   
GGT versus 
Independent correlates of 
GGT 
GGT versus 
Variables  r P Beta P 
Age  -0.07 0.03 0.03 0.38 
Male gender  0.27 <0.001 0.14 <0.001 
Diabetes 0.008 0.79 -0.01 0.70 
Smoking  0.09 0.003 0.008 0.77 
CV comorbidities  0.14 <0.001 0.09 0.001 
Alcohol consumption  0.20 <0.001 0.11 <0.001 
BMI  0.09 0.006 0.02 0.47 
Systolic BP 0.02 0.56 0.03 0.28 
Diastolic BP  -0.01 0.74 ….. …... 
Lipid-lowering agents 0.01 0.69 0.02 0.44 
Glucose  0.16 <0.001 ….. …… 
LDL cholesterol 0.03 0.35 0.03 0.31 
Haemoglobin  0.23 <0.001 0.10 0.003 
C reactive protein 0.16 <0.001 0.14 <0.001 
Alkaline Phosphatase  0.16 <0.001 0.11 <0.001 
Homocysteine  0.07 0.02 0.06 0.03 
AST  0.31 <0.001 -0.02 0.69 
ALT  0.39 <0.001 0.38 <0.001 
oxLDL  0.10 0.002 0.09 0.004 




P=0.02)] adjusting for the full list of traditional and non-traditional risk factors 
considered in this study (Supplementary Table II). 
 
Supplementary Table II. Multiple logistic regression model of past CV events 
 
 
Units of increase 
Past CV disease 
Odds ratio  
(CI 95%)  
P value 
GGT 20 U/L 1.24 (1.07-1.44)  0.005 
Age  1 year 1.03 (0.99-1.07)  0.06 
Male gender  4.05 (2.54-6.46)  0.001 
Current smokers yes/no 1.32 (0.79-2.20)  0.28 
BMI 1 Kg/m2 0.97 (0.91-1.03)  0.31 
LDL cholesterol 1 mg/dl 0.99 (0.99-1.01)  0.38 
C reactive protein 1 g/mL 1.02 (1.00-1.04)  0.05 
Systolic blood pressure 1 mmHg 1.00 (0.99-1.01)  0.94 
Alkaline phosphatase 1 U/L 1.00 (0.99-1.01)  0.55 
Haemoglobin 1 g/dL 0.97 (0.84-1.13)  0.72 
Alcohol consumption 1 g/day 0.99 (0.98-1.01)  0.05 
AST 1 U/L 0.99 (0.95-1.03)  0.55 
ALT 1 U/L 0.98 (0.95-1.01)  0.18 
Diabetes yes/no 1.55 (0.90-2.67)  0.11 
Creatinine clearance 1 ml/min/1.73m2 1.00 (0.99-1.02)  0.78 
oxLDL 1 U/L 1.01 (0.99-1.03)  0.10 
Homocysteine  µmol/L 0.98 (0.95-1.01)  0.18 
Abbreviations: GGT= gamma-glutamyltransferase; BMI=body mass index; AST= aspartate 
aminotransferase; ALT=alanine aminotransferase; oxLDL=oxidized low-density lipoproteins 
 
 
GGT, all-cause and CV mortality 
During the follow-up period (median 9 years, range 0.15- 10.5 years), 401 individuals 
died, 168 of them (42%) for cardiovascular causes. In an age and sex adjusted Cox 
regression model, 20U/L increase in serum GGT signaled a parallel 10% increase in the 
risk of all-cause mortality (HR:1.10, 95%CI:1.03-1.18, P=0.007). In a multiple Cox 
regression analysis adjusting for the same set of variables applied in the multiple 
logistic regression model (Supplementary Table III), GGT was confirmed as an 
independent risk factor of mortality [HR (20 U/L increase):1.11, 95%CI:1.02-1.21, 
P=0.02]. Similarly, GGT predicted CV mortality both in age and sex adjusted model 
(HR:1.12, 95%CI:1.01-1.24; P=0.04) and in an analysis [(HR:1.17, 95%CI:1.03-1.34; 
P=0.02); shrinkage corrected HR:1.17, 95%CI: 1.02-1.33; P=0.02)] adjusting for the 




same set of variables applied in the multiple logistic regression model. In sensitivity 
analyses (N=937) excluding patients who died for malignancies or within 1 year from 
the enrolment, the HR of GGT for all-cause [HR (20 U/L increase):1.13, 95%CI:1.02-
1.25, P=0.02] and CV death (shrinkage corrected HR:1.17, 95%CI:1.03-1.34, P=0.02) 
remained the same.  
 
Supplementary Table III. Multiple Cox regression models of all-cause and CV mortality 
 
 
Units of increase 
All-cause mortality CV mortality 
Hazard ratio 
(CI 95%) 
P value *Hazard ratio 
(CI 95%) 
P value 
GGT 20 U/L 1.11 (1.02-1.21) P=0.02 1.17 (1.03-1.33) 0.02 
Age 1 year 1.13 (1.11-1.15) P<0.001 1.14 (1.11-1.17) <0.001 
Male gender  1.26 (0.98-1.63) P=0.08 1.55 (1.04-2.29) 0.03 
Current smokers yes/no 1.93 (1.43-2.63) P<0.001 1.22 (0.67-2.22) 0.51 
BMI 1 Kg/m2 1.01 (0.98-1.04) P=0.49 1.04 (0.99-1.09) 0.10 
LDL cholesterol 1 mg/dl 0.99 (0.98-0.99) P=0.007 1.00 (0.99-1.01) 0.36 
C reactive protein 1 g/mL 1.01 (1.01-1.02) P=0.006 1.01 (1.00-1.02) 0.02 
Systolic BP 1 mmHg 1.01 (0.99-1.01) P=0.17 1.01 (0.99-1.01) 0.10 
Alkaline phosphatase 1 U/L 1.00 (1.00-1.01) P=0.01 1.00 (0.99-1.01) 0.47 
Hemoglobin 1 g/dL 1.04 (0.96-1.13) P=0.32 1.14 (1.01-1.30) 0.04 
Alcohol consumption 1 g/day 0.99 (0.98-0.99) P=0.03 0.98 (0.97-0.99) <0.001 
AST 1 U/L 1.01 (0.99-1.04) P=0.26 1.01 (0.97-1.04) 0.79 
ALT 1 U/L 0.98 (0.96-0.99) P=0.01 0.97 (0.95-1.01) 0.11 
Diabetes yes/no 1.17 (0.85-1.61) P=0.35 1.22 (0.73-2.03) 0.45 
Creatinine clearance 1ml/min/1.73m2 1.00 (0.99-1.01) P=0.80 0.99 (0.98-1.00) 0.09 
oxLDL 1 U/L 1.01 (0.99-1.02) P=0.18 0.99 (0.98-1.01) 0.51 
Past CV events yes/no 1.48 (1.15-1.92) P=0.002 1.37 (0.92-2.05) 0.12 
Homocysteine µmol/L 1.02 (1.00-1.03) P=0.002 1.02 (1.00-1.04) 0.05 
Abbreviations: GGT= gamma-glutamyltransferase; BMI=body mass index; LDL= low-density lipoproteins; AST= 
aspartate aminotransferase; ALT=alanine aminotransferase; oxLDL= oxidized low-density lipoproteins.  
* Shrinkage corrected. 
 
GGT and clinical outcomes: effect modification by oxidized low-density lipoprotein  
Because oxLDL and GGT reflect reactive oxygen species burden, we hypothesized that 
coexistence of high oxLDL and GGT may amplify the risk for all-cause and CV mortality 
in the elderly population of the InCHIANTI study. Oxidized LDL per sé failed to show a 
meaningful link with all-cause and CV death (HR:0.99 for both outcomes). However, 
oxLDL amplified the effect of GGT on all-cause mortality both in age and sex adjusted 
Cox models (P for the effect modification=0.001) and adjusted analyses (P for 




Table 2. Multiple Cox regression model of the oxLDL-GGT interaction for all-cause mortality 
 
 
Units of increase 
All-cause mortality 
Hazard ratio  









See Figure 1 
 
 
P for interaction=0.003 
Age  1 year 1.13 (1.11-1.15)  0.001 
Male gender  1.26 (0.98-1.63)  0.07 
Current smokers yes/no 1.91 (1.41-2.59)  0.001 
BMI 1 Kg/m2 1.01 (0.98-1.04)  0.59 
LDL cholesterol 1 mg/dl 0.99 (0.98-0.99)  0.007 
C reactive protein 1 g/mL 1.01 (1.01-1.02)  0.006 
Systolic blood pressure 1 mmHg 1.00 (0.99-1.01)  0.26 
Alkaline phosphatase 1 U/L 1.00 (1.00-1.01)  0.005 
Hemoglobin 1 g/dL 1.04 (0.96-1.12)  0.34 
Alcohol consumption   1 g/day 0.99 (0.98-0.99)  0.04 
AST 1 U/L 1.01 (0.99-1.04)  0.21 
ALT 1 U/L 0.98 (0.96-0.99)  0.02 
Diabetes yes/no 1.17 (0.85-1.62)  0.33 
Creatinine clearance 1 ml/min/1.73m2 1.00 (0.99-1.01)  0.70 
Past CV events yes/no 1.43 (1.11-1.85)  0.006 
Homocysteine  µmol/L 1.02 (1.01-1.03)  0.002 
Abbreviations: GGT= gamma-glutamyltransferase; oxLDL=oxidized low-density lipoproteins; BMI=body 
mass index; LDL=low-density lipoproteins; AST= aspartate aminotransferase; ALT=alanine aminotransferase 
 
 
Figure 2. Effect modification of oxLDL levels on the GGT-mortality link (adjusted for age, gender, smoking, BMI, 
LDL cholesterol, C reactive protein, systolic BP, alkaline phosphatase, hemoglobin, alcohol consumption, AST, 
ALT, homocysteine, diabetes, creatinine clearance and past CV events). The hazard ratio for all-cause mortality 
portended by a fixed increase (20U/L) in serum GGT is reported on the left scale. The continuous line 
represents the shape of the HRs throughout oxLDL levels and the dotted lines the corresponding 95% CI. In 
the background the distribution of oxLDL is plotted and the number of patients corresponding to each column 
of the histogram is reported on the right scale.  




As shown in Figure 2, the risk excess for all-cause mortality portended by a fixed 
increase in GGT (20 U/L) was progressively higher across increasing values of oxLDL. 
A sensitivity analysis excluding individuals who were heavy drinkers (n=194), 
confirmed the oxLDL-GGT interaction for all-cause mortality (P<0.001).  Of note, this 
interaction was specific because no similar effect modification existed for AST, ALT, 
CRP, smoking, alcohol consumption and other traditional or non-traditional risk 
factors (P ranging from 0.16 to 0.97).  
An interaction analysis carried out to test the effect modification by oxLDL on the GGT-
CV mortality link (Supplementary Table IV) showed a similar trend in age and sex 
adjusted Cox model (P for interaction=0.02) but this interaction just failed to achieve 
the formal statistical significance in both a fully adjusted analysis (P for 
interaction=0.08) and a sensitivity analysis (P=0.18) excluding heavy drinkers. 
 
 
Supplementary Table IV.  Multiple Cox regression model of the oxLDL- GGT interaction for CV 
mortality 
 
Units of increase 
CV mortality 
Hazard ratio (CI 95%)  P value 
GGT 20 U/L  
*P for interaction=0.08 oxLDL 1 U/L 
GGT x oxLDL (interaction term) 20 U2/L2 
Age  1 year 1.15 (1.11-1.18)  0.001 
Male gender  1.59 (1.07-2.36)  0.02 
Current smokers yes/no 1.22 (0.67-2.20)  0.52 
BMI 1 Kg/m2 1.04 (0.90-1.09)  0.10 
LDL cholesterol 1 mg/dl 1.00 (0.99-1.01)  0.35 
C reactive protein 1 g/mL 1.01 (1.00-1.02)  0.009 
Systolic blood pressure 1 mmHg 1.00 (0.99-1.01)  0.10 
Alkaline phosphatase 1 U/L 1.00 (0.99-1.01)  0.40 
Hemoglobin 1 g/dL 1.15 (1.02-1.30)  0.03 
Alcohol consumption   1 g/day 0.98 (0.97-0.99)  <0.001 
AST 1 U/L 1.00 (0.97-1.04)  0.69 
ALT 1 U/L 0.97 (0.94-1.01)  0.10 
Diabetes yes/no 1.26 (0.75-2.09)  0.38 
Creatinine clearance 1 ml/min/1.73m2 0.99 (0.98-1.01)  0.08 
Past CV events yes/no 1.34 (0.89-2.00)  0.16 
Homocysteine  µmol/L 1.02 (1.00-1.04)  0.04 
*Given the fact that the interaction did not achieve statistical significance (P=0.08), no shrinkage 






In this cohort study conducted in older persons living in the Chianti area of Italy, serum 
GGT levels associated with history of CV disease and predicted the risk for all-cause 
and CV death independently of other risk factors, including liver disease and alcohol 
consumption. Furthermore, in a pre-specified interaction analysis circulating oxLDL 
amplified the effect of GGT on mortality. 
Meta-analyses of studies in the general population and in high risk conditions (4, 5) 
coherently showed that GGT predicts an excess risk for death and fatal CV events. 
Importantly, the excess risk by GGT for these outcomes is largely independent of liver 
disease and alcohol consumption, i.e. the two major environmental factors 
responsible for raised GGT in human diseases. Of note the strength of the association 
between GGT and all-cause mortality was second only to that by age and CRP and the 
same outcome, further emphasising the relevance of non-traditional risk factors in the 
elderly (15). The vast majority of these studies were based on cohorts of young and 
middle-aged adults (4, 5). Until now just one community study specifically focused on 
an elderly population (the Rancho Bernardo study) (8). In this elderly population, GGT 
emerged as an independent predictor of all-cause and CV death. This observation 
contrasts with age-stratified analyses in the Minnesota Heart Survey where GGT was 
unrelated to CV death in people older than 70 years (9). Similarly, GGT failed to predict 
CV mortality in men older than 55 years in the British Regional Heart study cohort (12). 
Remarkably, an age-dependent attenuation of the health risk signalled by GGT was 
registered not only for the independent risk of CV death (16) but also for the incident 
risk of cancer (17). The age-dependent attenuation of the risk by GGT on major clinical 
outcomes suggests that the duration of exposure to this risk factor is critical to explain 
its link with adverse outcomes. In other words, shorter life expectancy in elderly 
people and competing risks by other diseases may prevent capturing any underlying 
link between GGT and mortality or CV disease in the elderly.  
The InCHIANTI study is based on a cohort of prevalently healthy elderly people. Life 
expectancy in Tuscany (85 years for women and 80 years for men) is among the 




longest worldwide and the InCHIANTI study has a quite long follow up with a median 
time of observation of 9 years. In this prevalently healthy cohort in subjects free of 
liver disease at baseline, GGT emerged as coherent predictor of death and fatal CV 
events independently of traditional (Framingham) and non-traditional risk factors 
including alcohol intake as well as CRP (18) and homocysteine (19), two established 
predictors of adverse outcomes in the elderly. High GGT is considered as a major 
biomarker of non-alcoholic fatty liver disease (NAFLD) (20) which is seen as a 
manifestation of metabolic syndrome (21). However, both in our study and in the 
Rancho Bernardo study (8) the link between GGT and mortality was largely 
independent of BMI and other variables underlying the metabolic syndrome 
suggesting  that the independent risk of GGT for adverse clinical outcomes may 
underlie mechanism other than the metabolic syndrome. 
GGT plays a crucial role in oxidative processes favouring the cellular supply of 
glutathione (GSH), the major thiol antioxidant in human body (2). GGT is ubiquitously 
expressed to the cell-surface where it promotes the extracellular catabolism of GSH, 
allowing for precursor amino acids to be internalized and reused for intracellular GSH 
synthesis in a continuous “GSH cycling” across the plasma membrane (22). 
Accordingly, GGT associates directly with F2-isoprostanes, an established marker of 
oxidative stress (23) and inversely with serum antioxidants (24, 25). On the other 
hand, experimental data exists indicating that GGT may per sé trigger the production 
of ROS via a sulphur di-aminoacid (cysteinyl-glycine) generated from GSH hydrolysis 
(22, 26). 
Because GGT in atherosclerotic plaques co-localizes with oxLDL, this co-localization 
may be critical in the pathogenesis of atherosclerosis (6), a possibility supported by 
the observation that circulating GGT is bound to LDL (25). In a pre-specified interaction 
analysis we found an effect modification by oxLDL for the risk of death predicted by 
GGT levels. We observed a similar interaction for fatal CV events but, perhaps due to 
the relatively limited number of events, this effect just failed to achieve statistical 




mechanism which amplifies the toxic effects of oxLDL on the vascular system or vice 
versa.  
In conclusion, in this cohort study in a population of relatively healthy elderly people, 
GGT is directly associated with the incident risk of all-cause and CV death 
independently of a large set of potential confounders and circulating oxLDL amplifies 
the effect of GGT on all-cause but not CV mortality in older adults. This study supports 
the contention that GGT may have a role in oxidative stress-mediated adverse health 
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Studies included in this thesis document that insulin resistance, inflammation and 
oxidative stress are crucial pathophysiological pathways that affect survival and CV 
integrity in high-risk populations. Observations from cross-sectional studies are 
supported by prospective evidence that gives consistent insights into the role of these 
detrimental processes in the high susceptibility to mortality and adverse CV outcomes 
in obese individuals and elderly subjects as well as in patients with CKD of various 
severity, representing a useful tool for risk stratification in these populations.  
 
Expression of inflammatory molecules in abdominal fat mass of obese individuals 
Adipose tissue is distributed throughout the body in discrete fat compartments and 
the topography of its accumulation is relevant for the risk of adverse clinical outcomes. 
Adipose tissue is an abundant source of inflammatory cytokines and an excess of fat 
mass has been associated with a chronic subclinical inflammatory state. Central 
adiposity is more strongly associated with inflammation than peripheral adiposity (1) 
but a large waist encompasses both increased abdominal subcutaneous adipose tissue 
(SAT) and visceral adipose tissue (VAT) not allowing to assess the specific contribution 
of these two fat compartments to obesity-related inflammation.  By comparing the 
expression profiles of 19 major pro-inflammatory and 7 anti-inflammatory genes in 
SAT and VAT of severely obese patients, I found that these two fat compartments 
express the same set of inflammatory cytokines and that the large majority of pro-
inflammatory genes is more expressed in SAT than in VAT, suggesting a stronger 
contribution of the subcutaneous fat compartment to the low-grade obesity-related 
inflammation. This evidence seems at odds with the traditional view of VAT as the 
main determinant of risk excess for adverse clinical complications and SAT as neutral 
or even protective component as for the same risk. However, the predominant 
component of fat mass in central adiposity is subcutaneous rather than visceral (2), 
being this latter just a minor segment of total fat depots equal to less than 1/5 of 




evidence showing higher gene expression of TNF IL6 and IL1(4-6) in SAT of obese 
patients rather than in VAT. I also found an upregulated expression of other two 
important pro-inflammatory molecules in SAT: SAA1 and PAI, which are responsible 
for the early response to injury and the inhibition of the fibrinolytic system, 
respectively. Moreover, I was able as first to demonstrate that IL8 is remarkably 
upregulated in SAT and that this increase was paralleled by an increase of the gene 
expression of the two IL8 receptors, pointing to an augmented IL8 signalling in SAT of 
obese individuals. In my study, IL18 was the sole pro-inflammatory cytokine showing 
a reverse expression pattern being upregulated in VAT. However, IL18 is a pleiotropic 
molecule promoting inflammation as well as the synthesis of anti-inflammatory 
cytokines such as IL10 (7). Of note, IL18-deficiency in mice causes hyperphagia, 
obesity, diabetes and atherosclerosis by massive fat deposition in the arterial walls 
(8). Thus, IL18 downregulation in SAT is in keeping with the hypothesis that the overall 
expression profile of cytokines in SAT denotes a more pro-atherogenic, metabolically 
adverse attitude.  
Likewise, leptin and resistin, two potent pro-inflammatory adipokines, are 
upregulated in SAT as well as adiponectin which is the major anti-inflammatory 
protein secreted by adipose tissue. In support of an increased pro-inflammatory gene 
expression of SAT compared to VAT, I found that macrophage infiltration was 
comparable in the two fat compartments. However, a strong and positive correlation 
between SAT and VAT gene expression for the majority of the pro-inflammatory genes 
studied indicate that, though at different rates, the two fat compartments undergo 
similar changes in the expression profile of inflammatory cytokines. Interestingly, 
although cytokines secreted by adipose tissue usually act as autacoids, I found a strong 
association between the gene expression and the corresponding plasma levels for 4 
inflammatory cytokines (IL8, IL18, SAA1, adiponectin) providing evidence that adipose 







TIMP-1, insulin resistance and cardiomyopathy in patients with kidney failure  
Left ventricular hypertrophy (LVH) and insulin resistance (IR) are pervasive 
complications of kidney failure (9, 10). LVH is characterized by hypertrophy of 
cardiomyocytes and abnormal accumulation of fibrous tissue in the interstitium of the 
myocardium (11). Ultrasonic studies in vivo in the myocardium of patients with kidney 
failure confirmed that fibrosis is a hallmark in LVH in this population (12, 13). There is 
consistent evidence that IR promotes myocardial fibrosis (14) by altering the balance 
between the synthesis and breakdown of extracellular matrix proteins (15). Indeed, 
raised insulin secretion shifts this balance toward reduction of extracellular matrix 
degradation via the phosphatidylinositol 3-kinase (PI 3-kinase)/protein kinase Akt 
pathway (16). The fibrogenic process is regulated by matrix metalloproteinases 
(MMPs) that are a family of enzymes which degrade matrix proteins in the 
extracellular environment. The proteolytic activity of MMPs is modulated by a group 
of endogenous inhibitors known as tissue inhibitors of metalloproteinases (TIMPs) 
(17). The balance between MMPs and TIMPs is critical for the eventual remodeling of 
the myocardial tissue. TIMP-1 is currently considered a promising marker of fibrosis 
(18, 19). High circulating levels of TIMP-1 have been associated with LVH in both the 
general population (20) and in hypertensive patients (21, 22) and, in experimental 
models of pressure overload, over-expression of this biomarker goes in parallel with 
an increased LV mass (23). I have shown that a polymorphism in a genetic marker, the 
ENPP1 (i.e. ectonucleotide pyrophosphatase/phosphodiesterase 1) gene, of IR 
modifies the relationship between the pro-fibrotic TIMP-1 and LV geometry and 
function in a population of dialysis patients. The ENPP1 gene codes for a membrane 
glycoprotein that alters the intracellular insulin signalling by inhibiting insulin receptor 
autophosphorylation (24). In a recent study in the same set of patients with kidney 
failure, I documented a strong and significant association between the rs1974201 
polymorphism in the ENPP1 gene and LV hypertrophy and concentric remodelling 
(25). Interestingly, in the latter study the ENPP1 rs1974201 polymorphism showed 




of a direct involvement of carbohydrate metabolism in the pathogenesis of 
cardiomyopathy in dialysis patients. In this frame, I speculated that this 
polymorphism, which contributes to insulin resistance, can also modify the link 
between TIMP-1 and LV geometry and function. In the whole study population, TIMP-
1 was directly and significantly (P=0.014) associated to E/A ratio, a marker of LV 
function, but unrelated to LV geometry as assessed by relative wall thickness (RWT) 
and LV mass-to-volume ratio. However, a separate analysis on stratified patients 
according to ENPP1 rs1974201 genotypes, shows that homozygous patients for the G 
allele exhibit a direct association of TIMP-1 with LV dysfunction but also a significant 
relationship between the same biomarker and the echocardiographic indices RWT and 
LV mass-to-volume ratio that increase of 22% and 14% respectively for a fixed increase 
in TIMP-1 levels (100 ng/ml). This finding points to the rs1974201 polymorphism as an 
effect modifier of the TIMP1-LV geometry and function. This is consistent with the 
hypothesis that the ENPP1 gene and IR are relevant players in the pathogenesis of 
concentric LVH as well as in the development of myocardial fibrosis in patients with 
kidney failure. 
 
The causal association between inflammation and CV complications in CKD: a 
Mendelian randomization study 
CKD is a clinical condition characterized by high CV risk and chronic systemic 
inflammation (26, 27). Although inflammation and CV disease are closely associated, 
being inflammation a critical component of the atherosclerosis process (28), the 
nature (casual vs non-causal) of this link remains elusive in CKD patients. 
Observational studies, indeed, are methodologically vulnerable to test causality 
because of potential bias and confounding. In this frame, the Mendelian 
randomization approach, by exploiting functional genetic polymorphisms as indicators 
of the effect of modifiable environmental exposures on disease, may offer the 
opportunity to overcome problems inherent to non-experimental studies. The 





“natural” randomization which mimics the effects of a randomized clinical trial. By 
using this approach, I reported a strong and significant association between 
inflammation and adverse CV events in CKD patients and, notably, offered strong 
support to the hypothesis that this link is causal in nature, this finding being relevant 
because of the presence of inflammation at all CKD stages (29). IL-6 is an orchestrator 
of the inflammatory response and high circulating levels of this cytokine are predictive 
of mortality and CV events in several populations (30, 31), including dialysis patients 
(32-36). I used a functional polymorphism, i.e. the-174 G/C, in the promoter region of 
the IL-6 gene, as a reliable research tool for testing the nature (causal vs non causal) 
of the association between inflammation and CV complications in a population of 
patients with CKD of various severity. The -174 G/C is a single nucleotide 
polymorphism (SNP) which regulates circulating levels of IL-6 by modulating the rate 
of IL-6 gene transcription (37-43). In keeping with previous studies in patients with CV 
complications (37-41, 43), I found that, by stratifing the study population according to 
the -174 G/C polymorphism, CKD patients with CC genotype had higher circulating 
levels of IL-6 than those harboring GC or GG genotypes. Interestingly, I found that this 
polymorphism was independently associated with the history of CVD as well as with 
incident CV events and such associations went along with the relationships between 
serum IL-6 and the same outcomes in our cohort, specifically legitimating the use of 
this genetic marker as an unbiased means for assessing the causal nature of the link 
between the gene product (IL-6) of this polymorphism and the CV complications in 
CKD. Further, the observation that in our patients the -174 G/C polymorphism was not 
in Hardy-Weinberg equilibrium and that the frequency of the C allele was significantly 
higher in CKD patients than in the general population from the same geographical 
area, offers additional circumstantial evidence that IL-6 is a causal risk factor for CV 
events in CKD (44). 
To the best of my knowledge, this was the first study which tested the association 
between IL-6 and CV events and investigated the causality of this link in a population 




carried out by Barreto et al. (45) in a small CKD cohort (n=125) characterized by a quite 
limited number of CV events (n=22) and including 34% of dialysis patients. In addition, 
in the study by Barreto, the nature of the association between inflammation and CV 
outcomes was not tested because being observational in nature and based only on 
circulating IL-6, this study remains merely hypothesis generating thus leaving 
unresolved the critical question whether IL-6 is causally implicated in CV complications 
in CKD patients. Although, this issue demands specific experimental evidence (i.e. a 
formal randomized clinical trial), our Mendelian randomization study supports causal 
interpretations. As for the potential limitations to Mendelian randomization 
application, it is reasonable to believe that in our study all the assumptions required 
to consider this approach as an effective analysis strategy to infer causality in 
observational setting, are fulfilled. In fact, the -174G/C SNP is a functional 
polymorphism directly responsible for serum levels of IL-6 (37-43), our population is 
genetically homogeneous (46) and pleiotropy seems highly unlikely because of the 
location of the polymorphism in the promoter region of the gene. Remarkably, in line 
with our findings, meta-analytic data from genetic consortia exploring the effect of a 
polymorphism in the interleukin-6 receptor (IL6R) on the risk of coronary artery 
disease, showed that the allele which attenuated IL-6 signaling was significantly 
associated with reduced risk of coronary heart disease (46). Finally, a meta-analysis of 
clinical trials testing a monoclonal antibody against the IL6R (Tocilizumab) in 
rheumatoid arthritis documented that lowering serum levels of IL-6 is an effective 
strategy to induce the remission of this chronic inflammatory disease (47).  
 
Fat-mass and obesity-associated (FTO) gene and mortality in CKD  
About half of the fat mass variations is explained by genetic factors (48) and, among 
the large series of genes associated to human obesity, the FTO (fat-mass and obesity-
associated) gene is of particular interest to investigate the complex relationship 
between high body mass index (BMI) and survival. This link deserves particular 





adiposity is directly and linearly associated with the risk of death, in CKD the 
relationship between obesity and mortality is U shaped or inverse, suggesting a 
protective effect of a high body fat mass in this population. Herein, I report an 
association between a polymorphism in the FTO gene and all-cause mortality in 
patients with CKD of various severity. I selected 17 tag SNPs that reflected the 
haploblock structure of the gene and captured the majority of the gene variability and 
explored their potential association with mortality in a cohort (the CREED-1 cohort) of 
dialysis patients. Among these polymorphisms, the rs708259 on intron 8 of the FTO 
gene resulted to be significantly associated with death. Specifically, in the CREED-1 
cohort, patients with the A allele of the rs708259 polymorphism showed a 52% higher 
risk of mortality than patients without this allele. When I extended the analysis to 
other two dialysis cohorts, the North Apulian and the CREED-2 cohort, including 
patients comparable to those of the CREED-1 cohort as for demographic and clinical 
characteristics, I observed again excess mortality (+23% and + 21%, respectively) in A-
allele carriers. Interestingly, I found such an association also in a third independent 
cohort of stage 2-5 CKD patients where A-allele carriers had an almost double risk of 
mortality relative to patients without A allele. While the association between the 
rs708259 polymorphism and mortality in my patients is statistically robust, the 
functional significance of this polymorphism is unknown. Because the rs708259 
polymorphism is unrelated to BMI and diabetes in my patients, it seems unlikely that 
the FTO gene affects survival through its impact on mechanisms regulating energy 
balance or glucose metabolism. Interestingly, despite the well-known association of 
the FTO gene with obesity (49-53) and type 2 diabetes (49, 54-55), polymorphisms in 
this gene associate also with other major clinical conditions including cancer (56-58), 
hypertension (59), Alzheimer’s disease (60) and kidney failure (61). Functionally, this 
gene codes for an enzyme that demethylates single-stranded DNA (62) and, thus, I 
speculate that this polymorphism may modulate relevant epigenetic modifications of 
other genes regulating various biological processes. Alternatively, the rs708259 




transcript and/or the protein product of FTO but functional studies in appropriate 
models are needed to mechanistically interpret the association between this 
polymorphism and mortality in patients with CKD. 
 
The mutual relationship between resistin and adiponectin on all-cause and CV 
mortality in ESKD patients 
Resistin is a cysteine rich molecule synthesized in the adipose tissue (63, 64) and high 
levels of this peptide go along with inflammation and insulin resistance both in 
experimental models (63, 65-66) and in man (67,68). Specifically, adipocytes are 
considered the sole source of resistin in mice (63, 64) while in man this adipokine is 
expressed primarily in macrophages and its levels correlate more closely with 
inflammation than with insulin resistance (70-72). Plasma resistin is markedly elevated 
in ESKD (73, 74) but it is still debated if this phenomenon is a mere consequence of 
accumulation secondary to reduced renal clearance or if it mainly reflects chronic 
inflammation (74). In line with this evidence, in a population of ESKD patients, I found 
that resistin was not only higher than in normal subjects but also significantly related 
with serum level of C reactive protein, a recognized marker of inflammation, while it 
did not correlate with insulin resistance as assessed by circulating levels of insulin and 
HOMA-IR index.  
Since resistin induces the expression of crucial pro-atherosclerotic mediators (75, 76), 
its role in CV risk was repeatedly questioned but evidence acquired so far is conflicting. 
Plasma resistin levels have been associated with coronary artery calcification (69), CV 
events and all-cause mortality in type 2 diabetes patients (77) as well as with major 
CV complications in the general population (78). However, no association between 
resistin and mortality was reported in patients with coronary artery disease (79). ESKD 
patients are a population with exceedingly high risk for death and CV events (80), thus 
testing the hypothesis that resistin is implicated in the high CV risk of these patients is 
a relevant question. Our study is the very first investigating the relationship between 





association between resistin and all-cause and CV mortality that was statistically 
strong and quantitatively of potential clinical relevance. However, the effect of resistin 
on study outcomes was closely dependent on concurrent ADPN levels, being apparent 
and highly significant only in patients with low ADPN. Indeed, by a fixed increase in 
plasma resistin, there was a consistent excess risk for death and fatal CV events in 
patients in the first ADPN tertile whereas no risk excess for these outcomes was 
apparent in patients in the third ADPN tertile. This interaction being fully independent 
of potential confounders and in line with the evidence that adipose tissue cytokines 
have mutual inter-relationships that contribute to determine death and CV 
complications (81). The effect of ADPN on the relationship between resistin and all-
cause and CV mortality has biological plausibility because ADPN and resistin have 
opposite effects on endothelial function and atherosclerotic process: resistin is a 
noxious factor for the CV system while ADPN is protective. Therefore, in ESKD patients, 
high ADPN reduces the CV risk excess sustained by high resistin levels. 
 
The role of the pro-oxidant GGT on survival in an Italian elderly population 
Gamma-glutamyltransferase (GGT) is a biomarker of liver disease (82, 83) but recent 
evidence supports an involvement of this enzyme in oxidative stress (84, 85), thus 
suggesting a potential role of GGT in the pathogenesis of CV disease (86). Since aging 
is a process heavely influenced by oxidative stress (87), eldelrly individuals provide a 
unique opportunity to study the relationship between GGT and CV outcomes. In this 
population-based cohort study conducted in people older than 65 years living in the 
Chianti area (Tuscany region) of Italy, I found that serum GGT levels associated with 
history of CV disease and predicted the risk for all-cause and CV death independently 
of a large set of risk factors, including liver disease and alcohol consumption, which 
are the two major environmental factors responsible for raised GGT levels in human 
diseases. These results are in line with meta-analyses data showing that GGT predicts 
an excess risk for death and fatal CV events in the general population and in patients 




studies included in the meta-analyses were carried out in cohorts of young and 
middle-aged adults (82, 83). Similarly, in the only community study (the Rancho 
Bernardo study) specifically focused on an elderly population (88), GGT emerged as an 
independent predictor of all-cause and CV death. In contrast, in an age-stratified 
analyses in the Minnesota Heart Survey, GGT resulted to be unrelated to CV death in 
people older than 70 years (89) and such a result was observed in the British Regional 
Heart study cohort where GGT failed to predict CV mortality in men older than 55 
years (90). Remarkably, an age-dependent attenuation of the health risk signalled by 
GGT was registered not only for the risk of CV death (91) but also for the risk of cancer 
(92). The age-dependent attenuation of the risk by GGT on major clinical outcomes 
suggests that the duration of exposure to this risk factor is critical to explain its link 
with adverse outcomes. In other words, the short life expectancy of elderly people 
and competing risks by other diseases may prevent identifying an underlying link 
between GGT and mortality or CV disease in the elderly. The InCHIANTI study is based 
on a cohort of prevalently healthy elderly people. Life expectancy in Tuscany (85 years 
for women and 80 years for men) is among the longest worldwide and the InCHIANTI 
study has a quite long follow up with a median time of observation of 9 years. In this 
cohort with subjects free of liver disease at baseline, GGT emerged as coherent 
predictor of death and fatal CV events independently of other risk factors including 
alcohol intake. High GGT is a major biomarker of non-alcoholic fatty liver disease 
(NAFLD) (93), which may be considered as the hepatic manifestation of metabolic 
syndrome (94). However, both in our study and in the Rancho Bernardo study (88), 
the link between GGT and mortality was largely independent of BMI and other 
variables underlying the metabolic syndrome, suggesting that GGT may induce 
adverse clinical outcomes via mechanism(s) other than the metabolic syndrome.  
GGT is ubiquitously expressed on the cell-surface where it promotes the extracellular 
catabolism of glutathione (GSH), allowing for precursor amino acids to be internalized 
and reused for intracellular GSH synthesis in a continuous “GSH cycling” across the 





a crucial antioxidant in human body (84), GGT plays a key role in oxidative processes. 
In addition, GGT may also trigger the production of ROS via a sulphur di-aminoacid 
(cysteinyl-glycine) generated from GSH hydrolysis (95, 96). Clinical evidence of the 
pro-oxidant action of GGT exists, indicating a direct correlation between GGT and F2-
isoprostanes, an established marker of oxidative stress (97), and an inverse association 
of this hepatic enzyme with serum antioxidants (98, 99). 
Recently, catalytically active GGT has been found within atherosclerotic coronary 
plaques (100) where it co-localizes with oxidized low-density lipoproteins (oxLDL). 
Serum GGT is partially adsorbed onto LDL which carry GGT inside the plaque (101), 
where this enzyme promotes the oxidation of LDL, likely contributing to oxidative 
events influencing plaque evolution and rupture (102). In light of the 
pathophysiological relationship between GGT and oxLDL, I observed that oxLDL 
modifies the risk of death predicted by GGT levels by amplifying the effect of GGT on 
all-cause and CV mortality in models controlling for potential confounders, suggesting 
that GGT levels may underlie a mechanism which amplifies the toxic effects of oxLDL 
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In this thesis, epidemiologic and genetic data analyses in high-risk populations for 
cardiovascular disease (CVD) and excess mortality show that insulin resistance, 
inflammation and oxidative stress are crucial pathophysiological pathways mediating 
the increased susceptibility to adverse cardiovascular (CV) outcomes and mortality. 
Specifically, findings from the cross-sectional study in severely obese subjects point to 
a prevailing role of the abdominal subcutaneous adipose tissue (SAT) on visceral 
adipose tissue (VAT) with respect to inflammatory gene expression, generating the 
hypothesis that topography of fat accumulation is relevant for the risk of inflammation 
and, consequently, of CV complications. Furthermore, a polymorphism in the 
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene, a genetic 
marker of insulin resistance associated with myocardial hypertrophy and LV 
concentric remodeling in dialysis patients, modifies the relationship between a 
myocardial pro-fibrotic cytokine, the tissue inhibitors of metalloproteinase 1 (TIMP-
1), and left ventricular (LV) geometry and function.  
The crucial role of fat mass in the increased risk of adverse and/or fatal clinical events 
has also been prospectively investigated in both chronic kidney disease (CKD) and end-
stage kidney failure (ESKF).  In relation to the endocrine function of the adipose tissue, 
a study in a cohort of patients with kidney failure shows a mutual relationship between 
resistin and adiponectin (ADPN) in determining death and CV events. Indeed, the risk 
for all-cause and CV mortality portended by a fixed increase in plasma resistin depends 
on plasma ADPN concentration, being evident in patients with low levels of ADPN but 
absent in those with high levels of this adipokine. In line with this evidence, the 
variability of the fat mass and obesity-associated (FTO) gene, a genetic biomarker of 
diabetes and hypertension, contributed to mortality in three cohorts of patients with 
CKD.   
In the context of inflammation as a trigger of CV complications, prospective follow up 
of patients with CKD revealed a strong and significant association between interleukin-




regulated, it was obvious to use a Mendelian randomization method that exploited a 
functional polymorphism in the IL-6 gene as instrumental variable: my findings 
strongly support that the link between serum IL-6 levels and CV complications is causal 
in nature. 
Finally, the role of oxidative stress on CV risk and mortality has been investigated in a 
cohort of healthy elderly since aging is, par excellence, the result of unbalanced pro-
oxidant processes. In the participants of the Invecchiare in Chianti study, gamma-
glutamyltransferase (GGT), a multifaceted biomarker of oxidative stress, emerged as a 
risk factor for all-cause and cardiovascular (CV) mortality independently of liver disease 
and alcohol intake. In addition, circulating oxidized low-density lipoproteins (oxLDL) 
amplified the effect of GGT on the adverse health outcomes. This supports the notion 
that GGT may underlie a mechanism which enhances the toxic effects of oxLDL on the 
































In dit proefschrift laten epidemiologische en genetische analyses zien dat insuline 
resistentie, inflammatie en oxidatieve stress cruciale pathofysiologische paden zijn en 
een verhoogde gevoeligheid voor ongunstige cardiovasculaire (CV) uitkomsten en 
mortaliteit mediëren in hoog-risicopopulaties voor cardiovasculaire aandoeningen 
(CVZ) en overmatige mortaliteit. 
In het bijzonder, laten de bevindingen van de cross-sectionele studie zien dat de rol van 
het abdominale subcutane vetweefsel (SAT) een belangrijkere rol heeft dan het 
visceraal vetweefsel (VAT) met betrekking tot inflammatoire genexpressie. Hierbij is de 
hypothese gegenereerd dat de lokalisatie van de vetophoping relevant is voor het risico 
van inflammatie en daarmee het risico op CV-complicaties. Daarnaast is gevonden dat 
een polymorfisme in het ectonucleotide pyrofosfatase / fosfodiesterase 1 (ENPP1) gen, 
een genetische marker van insulineresistentie geassocieerd met myocardiale 
hypertrofie en LV concentrische remodellering bij dialysepatiënten, de relatie tussen 
een myocardiaal pro-fibrotisch cytokine, de weefselremmers van metalloproteinase 1 
(TIMP-1), en linker ventrikel (LV) geometrie en functie modificeert. 
De cruciale rol van vetmassa in het verhoogde risico op nadelige en/of fatale klinische 
gebeurtenissen is tevens prospectief onderzocht bij zowel personen met chronische 
nierziekte (CKD) als eind stadium nierfalen (ESKF). Met betrekking tot de endocriene 
functie van het vetweefsel, toont een onderzoek in een cohort van patiënten met 
nierfalen een wederzijds verband tussen resistine en adiponectine (ADPN) bij het 
bepalen van overlijden en CV-events. 
Het risico voor mortaliteit door alle oorzaken en de CV mortaliteit dat wordt 
weergegeven door een forse toename in plasma resistine en afhangt van de ADPN-
concentratie in het plasma, is duidelijk bij patiënten met lage niveaus van ADPN maar 
afwezig bij patiënten met hoge niveaus van deze adipokine. In overeenstemming met 
dit bewijs, droeg de variabiliteit van het vetmassa- en het obesitas-geassocieerde (FTO) 
gen, een genetische biomarker van diabetes en hypertensie, bij aan de mortaliteit in 




In de context van inflammatie als een trigger voor CV-complicaties, toonde de 
prospectieve follow-up van patiënten met CKD een sterke en significante associatie 
tussen interleukine-6 (IL-6) en fatale en niet-fatale CV-gebeurtenissen. Omdat serum IL-
6 niveaus genetisch zijn gereguleerd, was het noodzakelijk om een Mendeliaanse 
randomisatiemethode te gebruiken die een functioneel polymorfisme in het IL-6-gen 
als instrumentele variabele exploiteerde: mijn bevindingen ondersteunen sterk dat de 
associatie tussen serum IL-6-niveaus en CV-complicaties causaal van aard is. 
Ten slotte is de rol van oxidatieve stress op CV-risico en mortaliteit onderzocht in een 
cohort van gezonde ouderen, omdat veroudering bij uitstek het resultaat is van 
ongebalanceerde pro-oxidantprocessen. In de deelnemers aan de Invecchiare in 
Chianti-studie kwam gamma-glutamyltransferase (GGT), een veelzijdige biomarker van 
oxidatieve stress, naar voren als een risicofactor voor mortaliteit door alle oorzaken en 
CV mortaliteit onafhankelijk van leverziekte en alcoholinname. Bovendien versterkten 
circulerende geoxideerde lipoproteïnen met lage dichtheid (oxLDL) het effect van GGT 
op de ongunstige gezondheidsresultaten. Dit ondersteunt het idee dat GGT mogelijk 
ten grondslag ligt aan een mechanisme dat de toxische effecten van oxLDL op het 
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